[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 187
1. de Haas ER, de Vijlder HC, van Reesema WS, van Everdingen JJ, Neumann HA: Quality of clinical practice guidelines in dermatological oncology. J Eur Acad Dermatol Venereol; 2007 Oct;21(9):1193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We searched MEDLINE, PubMed, EMBASE and Cochrane literature and relevant websites of guidelines development programmes and the national dermatological society to identify evidence-based dermatological guidelines especially in the treatment of to basal cell carcinoma, squamous cell carcinoma and melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894704.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


2. Applebaum KM, Karagas MR, Hunter DJ, Catalano PJ, Byler SH, Morris S, Nelson HH: Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. Environ Health Perspect; 2007 Aug;115(8):1231-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire.
  • UV damage is specifically repaired by nucleotide excision repair (NER), and common genetic variants in NER may increase risk for non-melanoma skin cancer (NMSC).
  • METHODS: Incident cases of basal and squamous cell carcinoma (BCC and SCC, respectively) were identified through a network of dermatologists and pathology laboratories across New Hampshire.
  • The analysis included 880 cases of BCC, 666 cases of SCC, and 780 controls.
  • RESULTS: There was an increased BCC risk associated with high arsenic exposure among those homozygous variant for XPA [odds ratio (OR) = 1.8; 95% confidence interval (CI), 0.9-3.7].
  • For XPD, having variation at both loci (312Asn and 751Gln) occurred less frequently among BCC and SCC cases compared with controls (OR = 0.8; 95% CI, 0.6-1.0) for both case groups.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1998 Aug;106 Suppl 4:1047-50 [9703491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81 [9950243.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:235-9 [10022259.001]
  • [Cites] Oncol Res. 1998;10(9):475-82 [10223623.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Aug 15;159(1):65-75 [10448126.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):295-9 [11872635.001]
  • [Cites] Environ Health Perspect. 1999 Sep;107(9):727-9 [10464073.001]
  • [Cites] Prensa Med Argent. 1964 Oct 23;51:994-8 [14231402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1788-93 [15533908.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2433-41 [15333465.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2242-6 [15598786.001]
  • [Cites] Hum Mutat. 2005 Apr;25(4):353-9 [15776433.001]
  • [Cites] Cancer Lett. 2005 May 26;222(2):205-9 [15863269.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):551-5 [10753184.001]
  • [Cites] Carcinogenesis. 2000 May;21(5):965-71 [10783319.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):874-97 [10841823.001]
  • [Cites] Pharmacology. 2000 Sep;61(3):212-27 [10971208.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1354-7 [11245433.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):559-65 [11257063.001]
  • [Cites] Carcinogenesis. 2001 Apr;22(4):593-7 [11285194.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3321-5 [11309287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):355-60 [11319176.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):899-904 [11375896.001]
  • [Cites] Mutat Res. 2001 Jul 1;478(1-2):159-68 [11406180.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1185-8 [11470747.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Dec 1;177(2):132-48 [11740912.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):152-5 [11782372.001]
  • [Cites] Carcinogenesis. 2002 Apr;23(4):599-603 [11960912.001]
  • [Cites] Int J Hyg Environ Health. 2002 Mar;205(1-2):85-94 [12018020.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):993-7 [12376498.001]
  • [Cites] Mutat Res. 2002 Nov 30;509(1-2):165-74 [12427537.001]
  • [Cites] J Invest Dermatol. 2003 Jan;120(1):48-55 [12535197.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):263-8 [12569548.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):505-9 [12663511.001]
  • [Cites] Toxicol Lett. 2003 Jul 20;143(2):123-31 [12749816.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):37-65 [14643412.001]
  • [Cites] Mutagenesis. 2004 Mar;19(2):143-8 [14981161.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):729-34 [14688016.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1604-9 [15381933.001]
  • [Cites] J Natl Cancer Inst. 1968 Mar;40(3):453-63 [5644201.001]
  • [Cites] Beitr Pathol. 1974 Apr;151(4):384-400 [4838015.001]
  • [Cites] Can Med Assoc J. 1975 Sep 6;113(5):396-401 [125622.001]
  • [Cites] Am J Epidemiol. 1976 Dec;104(6):609-20 [998608.001]
  • [Cites] Hum Toxicol. 1983 Jan;2(1):121-33 [6840787.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5895-9 [4053060.001]
  • [Cites] J Mol Biol. 1987 Aug 20;196(4):947-50 [3681984.001]
  • [Cites] J Clin Epidemiol. 1989;42(4):317-24 [2723692.001]
  • [Cites] Mol Toxicol. 1989 Winter;2(1):1-9 [2615768.001]
  • [Cites] Biol Trace Elem Res. 1989 Jul-Sep;21:373-81 [2484616.001]
  • [Cites] Biol Met. 1991;4(4):197-200 [1777354.001]
  • [Cites] Mutagenesis. 1992 Jan;7(1):51-5 [1635456.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):493-7 [8220096.001]
  • [Cites] Mutat Res. 2005 Jul 1;574(1-2):105-11 [15914210.001]
  • [Cites] Cancer Detect Prev. 2005;29(3):209-14 [15936590.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1539-44 [15941969.001]
  • [Cites] Mutat Res. 2006 Jun;612(3):215-46 [16574468.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1193-8 [16882524.001]
  • [Cites] Carcinogenesis. 2006 Aug;27(8):1670-5 [16513681.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):672-6 [17050553.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;84:1-477 [15645577.001]
  • [Cites] Am J Epidemiol. 1994 Oct 1;140(7):598-607 [7942760.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):109-14 [7819025.001]
  • [Cites] Mamm Genome. 1996 Aug;7(8):563-74 [8679005.001]
  • [Cites] Carcinogenesis. 1997 Feb;18(2):399-405 [9054635.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):345-51 [9219571.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):589-96 [9264271.001]
  • [Cites] Epidemiology. 1997 Sep;8(5):545-50 [9270957.001]
  • [Cites] Trends Biochem Sci. 1998 Jan;23(1):1-4 [9478126.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):604-8 [9485007.001]
  • [Cites] Mutat Res. 1998 Feb;407(1):25-34 [9539978.001]
  • (PMID = 17687452.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / R01CA082354; United States / NIEHS NIH HHS / ES / P42 ES007373; United States / NIEHS NIH HHS / ES / T32 ES07155; United States / NIEHS NIH HHS / ES / P42 ES07373; United States / NCI NIH HHS / CA / R01CA57494; United States / NIEHS NIH HHS / ES / T32 ES007155; United States / NCI NIH HHS / CA / R01 CA082354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Environmental Pollutants; 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human; N712M78A8G / Arsenic
  • [Other-IDs] NLM/ PMC1940098
  •  go-up   go-down


3. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther; 2010 Nov-Dec;23(6):651-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach.
  • Electroporation uses pulsed, high-intensity electric fields to temporarily increase cell membrane permeability by creation of pores, through which small molecules, such as chemotherapeutic agents, can diffuse inside cells before they reseal.
  • ECT has already been proven to be effective in diverse tumor histotypes, including melanoma and basal and squamous cell carcinoma, Kaposi sarcoma, and breast cancer, also in those cases nonresponding to classical chemotherapies or other loco-regional treatment modalities, with a good safety profile.
  • ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous tumor lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Electrochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Humans. Skin / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • (PMID = 21054709.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Thomas L, Dalle S: [Pathology of the eyelid in elderly patients]. J Fr Ophtalmol; 2006 Jun;29(6):672-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Illustrated review centered on diagnosis of the usual aspects and pitfalls of eyelid pathology divided into semiological chapters (tumors, blisters, erythema, etc.).
  • It is mainly centered on skin cancers (basal cell carcinoma, squamous cell carcinoma, adnexal carcinomas, and melanoma).
  • A number of rare diseases deserve mention since their presence could lead to the diagnosis of internal or systemic diseases (dermatomyositis, necrobiotic xanthogranuloma, Erdheim-Chester, etc.).
  • In such conditions, early diagnosis is often based on the observation of isolated periocular symptoms.
  • CONCLUSIONS: Even though topographic dermatology is a somewhat reductive vision of skin diseases, pathology of the eyelids deserves special mention because of its polymorphism as well as its diagnostic and/or therapeutic significance.
  • [MeSH-major] Eyelid Diseases / diagnosis
  • [MeSH-minor] Aged. Eyelid Neoplasms / diagnosis. Humans

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885900.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 123
  •  go-up   go-down


5. McGuire JF, Ge NN, Dyson S: Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior. Am J Otolaryngol; 2009 Mar-Apr;30(2):121-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior.
  • Non-Melanoma skin cancer (NMSC) is the most commonly encountered malignancy in almost every area of practice, but the cases that present to an Otolaryngology practice will be advanced in nature.
  • The major subtypes of NMSC include basal cell carcinoma, squamous cell carcinoma, dermatofibrosarcoma protuberans, merkel cell carcinoma, and adnexal malignancies.
  • [MeSH-major] Carcinoma / pathology. Dermatofibrosarcoma / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Neoplasm Metastasis. Organ Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239954.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


6. Caccialanza M, Piccinno R, Kolesnikova L, Gnecchi L: Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients. Int J Dermatol; 2005 Jun;44(6):513-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients.
  • BACKGROUND: The possibility of treating skin carcinomas of the pinna with radiotherapy is somewhat under discussion and scarcely known.
  • Therefore the aim of the study was to evaluate the effectiveness and safety of dermatologic radiotherapy in a series of patients affected by basal or squamous cell carcinoma of the pinna.
  • METHODS: A retrospective study was performed on 108 patients affected by 115 carcinomas of the pinna (99 basal cell carcinomas, 16 squamous cell carcinomas) without involvement of the external auditory canal.
  • During follow up a relapse was observed in 12 lesions (all basal cell carcinomas): nine central and three marginal to the irradiation field.
  • CONCLUSIONS: The results obtained confirm the possibility of treating epithelial skin neoplasms of the pinna with dermatologic radiotherapy, which can afford high-remission percentages without damaging cartilaginous tissue.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Ear Neoplasms / radiotherapy. Ear, External. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Esthetics. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941445.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Aboutalebi S, Strickland FM: Immune protection, natural products, and skin cancer: is there anything new under the sun? J Drugs Dermatol; 2006 Jun;5(6):512-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune protection, natural products, and skin cancer: is there anything new under the sun?
  • Non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma are the most common types of human neoplasms, representing one third of all new malignancies diagnosed in the US.
  • Ultraviolet (UV) radiation from the sun is a major cause of non-melanoma skin cancer in humans.
  • Aside from the mutagenic effects of UV radiation, there are suggestions from clinical studies and evidence in animal models that the immune system plays an important role in preventing skin cancer development and progression, and is suppressed by cutaneous exposure to UV radiation.
  • In this article, we review the research on new and existing agents that are being developed to protect the skin immune response from suppression by UV radiation.
  • [MeSH-major] Aloe. Antioxidants / therapeutic use. Carcinoma, Basal Cell. Phytotherapy. Skin Neoplasms. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16774102.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 1406-18-4 / Vitamin E; PQ6CK8PD0R / Ascorbic Acid
  • [Number-of-references] 67
  •  go-up   go-down


8. Thosani MK, Marghoob A, Chen CS: Current progress of immunostains in Mohs micrographic surgery: a review. Dermatol Surg; 2008 Dec;34(12):1621-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mohs micrographic surgery is often considered the treatment of choice for a variety of skin malignancies.
  • In recent years, the application of immunostaining techniques has facilitated the successful removal of a number of common and less common cutaneous malignancies, including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, dermatofibrosarcoma protuberans, microcystic adnexal carcinoma, sebaceous carcinoma, atypical fibroxanthoma, extramammary Paget's disease, and even sarcomas.
  • Immunostains highlight the tumor cells and allow the Mohs surgeons to pinpoint and eliminate the residual tumor at the surgical margin.
  • It is especially helpful when a tumor presents with subtle or nonspecific histologic features or when a tumor is masked in a pocket of dense inflammation.
  • [MeSH-major] Mohs Surgery / methods. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Staining and Labeling / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018832.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 127
  •  go-up   go-down


9. Basile J, Thiers B, Maize J Sr, Lathers DM: Chemokine receptor expression in non-melanoma skin cancer. J Cutan Pathol; 2008 Jul;35(7):623-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor expression in non-melanoma skin cancer.
  • Prior studies have shown that in metastatic melanoma and squamous cell carcinoma of the head and neck upregulation of CXC (alpha) chemokine receptor (CXCR)4 and CC (beta) chemokine receptor (CCR)7 expression is accompanied by downregulation of the chemokine receptor CCR6.
  • However, the expression patterns of CCR6, CCR7 and CXCR4 in non-melanoma skin cancer have yet to be elucidated.
  • METHODS: The expression patterns of CCR6, CCR7 and CXCR4 were determined using an immunohistochemical approach on formalin-fixed, paraffin-embedded normal, pre-cancerous actinic (solar) keratosis, squamous cell carcinoma and basal cell carcinoma tissues.
  • RESULTS: Analysis of chemokine receptor expression showed downregulation of CCR6 and upregulation of CCR7 and CXCR4 in potentially metastatic non-melanoma skin cancer, invasive squamous cell carcinoma, but this pattern did not exist in non-melanoma skin cancer with no metastatic potential, basal cell carcinoma; or actinic keratosis, when compared with normal skin.
  • CONCLUSIONS: Chemokine receptor expression may influence the biological behavior of non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis / metabolism. Receptors, CCR6 / metabolism. Receptors, CCR7 / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Analysis of Variance. Biomarkers / metabolism. Down-Regulation. Humans. Immunohistochemistry. Neoplasm Metastasis / physiopathology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Skin / metabolism. Skin / pathology. Staining and Labeling. Ultraviolet Rays / adverse effects. Up-Regulation

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312436.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CCR6 protein, human; 0 / CCR7 protein, human; 0 / CXCR4 protein, human; 0 / Receptors, CCR6; 0 / Receptors, CCR7; 0 / Receptors, CXCR4
  •  go-up   go-down


10. Chovanec M, Smetana K Jr, Plzák J, Betka J, Plzáková Z, Stork J, Hrdlicková E, Kuwabara I, Dvoránková B, Liu FT, Kaltner H, André S, Gabius HJ: Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia. Prague Med Rep; 2005;106(2):209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia.
  • Lectins represent one of pivotal regulators of the cell proliferation The potential of galectin-7 as a new prognostic marker was studied in normal and transformed squamous epithelia of both ectodermal (epidermis, cornea vs. trichoepithelioma, basal and squamous cell carcinoma) and endodermal (vocal fold epithelium vs. carcinoma) origin.
  • Its expression is significantly reduced in malignant cells, thus galectin-7 might be a differentiation marker of epithelial malignancies.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Epithelium / chemistry. Galectins / analysis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Division / physiology. Cells, Cultured. Humans. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315769.001).
  • [ISSN] 1214-6994
  • [Journal-full-title] Prague medical report
  • [ISO-abbreviation] Prague Med Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectins; 0 / LGALS7 protein, human
  •  go-up   go-down


11. Krathen MS, Gottlieb AB, Mease PJ: Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol; 2010 Nov;37(11):2205-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: It is unclear if skin cancer risk is affected by the use of immunomodulatory medications in rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA).
  • METHODS: The English language literature on PubMed was searched with a combination of phrases, including "malignancy," "skin cancer," "squamous cell carcinoma," "basal cell carcinoma," "melanoma," "psoriasis," "psoriatic arthritis," and "rheumatoid arthritis" in addition to the generic names of a variety of common immunomodulatory drugs.
  • Treatment with tumor necrosis factor inhibitors increases the rates of non-melanoma skin cancer (NMSC) in RA and psoriasis.
  • Methotrexate may increase the risk of malignant melanoma in patients with RA and the risk of NMSC in psoriasis.
  • More careful recording of skin cancer development during clinical trials and cohort studies is necessary to further delineate the risks of immunomodulatory therapy.
  • [MeSH-major] Arthritis, Psoriatic / therapy. Arthritis, Rheumatoid / therapy. Immunosuppression / adverse effects. Psoriasis / therapy. Skin Neoplasms / etiology


12. Mancuso M, Gallo D, Leonardi S, Pierdomenico M, Pasquali E, De Stefano I, Rebessi S, Tanori M, Scambia G, Di Majo V, Covelli V, Pazzaglia S, Saran A: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis; 2009 Feb;30(2):340-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.
  • Patched1 heterozygous mice (Ptch1(+/-)) are useful for basal cell carcinoma (BCC) studies, being remarkably susceptible to BCC induction by ultraviolet or ionizing radiation.
  • Analogously, skin carcinogenesis-susceptible (Car-S) mice are elective for studies of papilloma and squamous cell carcinoma (SCC) induction.
  • We previously reported a striking effect of gender on BCC induction in Ptch1(+/-) mice, with total resistance of females; likewise, Car-S females show increased skin tumor resistance relative to males.
  • Here, we investigated the protective role of endogenous estrogen in skin keratinocyte tumorigenesis.
  • Control (CN) and ovariectomized Ptch1(+/-) or Car-S females were irradiated for BCC induction or topically treated with chemical carcinogens for SCC induction.
  • Susceptibility to BCC or SCC was dramatically increased in ovariectomized Ptch1(+/-) and Car-S females and restored to levels observed in males.
  • Remarkably, progression of initially benign papillomas to malignant SCC occurred only in ovariectomized Car-S females.
  • We explored the mechanisms underlying tumor progression and report overexpression of estrogen receptor (ER)-alpha, downregulation of ERbeta and upregulation of cyclin D1 in papillomas from ovariectomized Car-S relative to papillomas from CN females.
  • Thus, an imbalanced ERalpha/ERbeta expression may be associated with estrogen-mediated modulation of non-melanoma skin carcinogenesis, with a key role played by cyclin D1.
  • Our findings underscore a highly protective role of endogenous estrogen against skin tumorigenesis by diverse agents in two independent mouse models of skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Estrogens / physiology. Skin Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Cyclin D1 / metabolism. Disease Models, Animal. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Female. Male. Mice. Neoplasms, Radiation-Induced / metabolism. Neoplasms, Radiation-Induced / pathology. Ovariectomy. Papilloma / metabolism. Papilloma / pathology. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Ultraviolet Rays


13. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST: Mast cells and cutaneous malignancies. Mod Pathol; 2006 Jan;19(1):149-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma.
  • Upon irradiation of the skin, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers.
  • These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma.
  • Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix.
  • Mast cell proteases reorganize the stroma to facilitate endothelial cell migration.
  • As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. (4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells.
  • Emerging data, however, also suggest that mast cells might, in fact, have opposing roles in tumor biology, and the microenvironment could polarize mast cells to possess either promoting or inhibitory effects on tumors.
  • [MeSH-major] Mast Cells / physiology. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / pathology. Humans. Melanoma / blood. Melanoma / blood supply. Melanoma / pathology. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258517.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 71
  •  go-up   go-down


14. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basosquamous carcinoma: treatment with Mohs micrographic surgery. Cancer; 2005 Jul 1;104(1):170-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma: treatment with Mohs micrographic surgery.
  • BACKGROUND: Basosquamous carcinoma (BSC) is a rare tumor defined as a basal cell carcinoma (BCC) differentiating into squamous cell carcinoma (SCC).
  • METHODS: The prospective, multicenter case series included all patients in Australia treated with MMS for BSC, who were monitored by the Skin and Cancer Foundation Australia between 1993 and 2002.
  • The tumors were diagnosed initially as BCC in 87.4% and as SCC in 12.0% of patients.
  • Of 98 patients who completed a 5-year follow-up period after MMS, 4 (4.1%) had disease recurrence.
  • CONCLUSIONS: The low 5-year disease recurrence rate of BSC with MMS emphasized the importance of margin-controlled excision using MMS.
  • [MeSH-major] Carcinoma, Basosquamous / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery / methods
  • [MeSH-minor] Adult. Aged. Arm. Female. Follow-Up Studies. Humans. Leg. Male. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929123.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


15. Kang SY, Lee KG, Lee W, Shim JY, Ji SI, Chung KW, Chung YK, Kim NK: Polymorphisms in the DNA repair gene XRCC1 associated with basal cell carcinoma and squamous cell carcinoma of the skin in a Korean population. Cancer Sci; 2007 May;98(5):716-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in the DNA repair gene XRCC1 associated with basal cell carcinoma and squamous cell carcinoma of the skin in a Korean population.
  • Unrepaired damage can result in apoptosis or may lead to unregulated cell growth and cancer.
  • This hospital-based case-control study examined whether polymorphisms in the DNA repair gene X-ray repair cross-complementing groups 1 (XRCC1) (Arg194Trp[C > T], Arg280His[G > A] and Arg399Gln[G > A]) play a role in susceptibility to skin cancer.
  • We genotyped these polymorphisms for 212 histopathologically confirmed skin cancer cases (n = 114 basal cell carcinoma, n = 98 squamous cell carcinoma) and 207 age- and sex-matched healthy control cases in Korea.
  • We found that individuals with the Arg/Gln and Arg/Gln + Gln/Gln genotypes at XRCC1 Arg399Gln(G > A) had an approximately 2-fold increased risk of basal cell carcinoma compared to individuals with the Arg/Arg genotype (adjusted odds ratio [AOR] = 2.812, 95% confidence interval [CI] 1.32-5.98, and AOR = 2.324, 95% CI 1.11-4.86).
  • However, we observed that the 194Trp allele of the Arg194Trp(C > T) polymorphism was inversely associated with squamous cell carcinoma risk (Trp/Trp, AOR = 0.06, 95% CI 0.006-0.63).
  • Our data suggest that the Arg194Trp and Arg399Gln polymorphisms may be differentially associated with skin cancer risk.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Skin Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group / genetics. Case-Control Studies. Gene Frequency. Genetic Predisposition to Disease / ethnology. Genotype. Haplotypes. Humans. Korea. Middle Aged. Odds Ratio

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355263.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1
  •  go-up   go-down


16. Wimmer E, Kraehn-Senftleben G, Issing WJ: HER3 expression in cutaneous tumors. Anticancer Res; 2008 Mar-Apr;28(2A):973-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In order to elucidate the role of the receptor tyrosine kinase HER3, the expression characteristics in different tissues of cutaneous malignancies and in normal skin were compared.
  • MATERIALS AND METHODS: In this study HER3 expression was evaluated by RT-PCR analysis and immunohistochemistry from different tissue specimens of cutaneous tumors like nevi, primary malignant melanomas, basal cell carcinoma, squamous cell carcinoma and malignant melanoma metastases and normal skin samples and graded into weak, moderate and strong expression.
  • Associations of tumor thickness in these specimens with HER3 expressions were also analyzed.
  • RESULTS: HER3 expression was found in 63% (10/16) of the basal cell carcinomas, in 4/5 of squamous cell carcinomas and in one Merkel cell carcinoma.
  • Within the group of different malignant melanomas, HER3 expression was detected in 35% of the nodular malignant melanomas (6/17) and in 9/19 of the superficial spreading melanomas, including 2 lentigo malignant melanomas.
  • The majority of melanomas with a higher tumor thickness expressed HER3, and 85% of melanoma metastasis were HER3-positive.
  • CONCLUSION: HER3 expression was associated with hyperproliferate tumor stages and suggested that HER3 expression could reflect an increased malignant potential in cutaneous lesions.
  • [MeSH-major] Skin Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Humans. Immunohistochemistry. Melanoma / genetics. Melanoma / metabolism. Neoplasm Metastasis. Nevus. Receptor, ErbB-3 / genetics. Receptor, ErbB-3 / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507044.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


17. Zhang H, Yan J, Li Y, Zhang P: Mucoepidermoid carcinoma of the eyelid: a case report and review of the literature. Yan Ke Xue Bao; 2005 Sep;21(3):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the eyelid: a case report and review of the literature.
  • PURPOSE: To report the clinical features, therapeutic method, and histopathological findings of a case of mucoepidermoid carcinoma in the lower eyelid and review the literature about the mucoepidermoid carcinoma arising from the eye.
  • RESULTS: An 88-year-old man developed a painless, indurated nodule in the left lower eyelid for two years and ulceration of the skin existed for a year.
  • He underwent tumor resection and reconstruction of the eyelid.
  • By histopathology, tumor cells showed an admixture of epidermoid and mucus-secreting cells, which was consistent with mucoepidermoid carcinoma.
  • Mucoepidermoid carcinoma is a common malignant tumor of the salivary glands, but rare in the eye tissues among which conjunctiva and lacrimal gland are most commonly involved.
  • It has a higher degree of malignancy than basal cell carcinoma and squamous cell carcinoma.
  • CONCLUSIONS: Mucoepidermoid carcinoma arising from the eye is rare and has a high degree of malignancy.
  • It should be differentiated from other neoplasms such as basal cell carcinoma and squamous cell carcinoma.

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162853.001).
  • [ISSN] 1000-4432
  • [Journal-full-title] Yan ke xue bao = Eye science
  • [ISO-abbreviation] Yan Ke Xue Bao
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 23
  •  go-up   go-down


18. Reisinger DM, Shiffer JD, Cognetta AB Jr, Chang Y, Moore PS: Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma. J Am Acad Dermatol; 2010 Sep;63(3):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma.
  • BACKGROUND: Merkel cell polyomavirus (MCV) was discovered by digital transcriptome subtraction as a monoclonal infection of Merkel cell carcinoma (MCC) tumors.
  • Polymerase chain reaction-based detection of the virus in other nonmelanoma skin cancers, however, has been inconsistent and controversial.
  • OBJECTIVE: We sought to directly assay for MCV infection in squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) tumor cells by immunostaining for viral antigen.
  • METHODS: CM2B4, a monoclonal antibody to exon 2 peptides of MCV T antigen, was used to examine tumors from 20 patients with MCC with and without secondary SCC or BCC tumors.
  • RESULTS: MCV T antigen was readily detected in 15 (75%) of 20 MCC tumors including 11 MCC tumors from patients with secondary SCC or BCC.
  • In contrast to MCC, none of these secondary BCC or SCC was MCV T-antigen positive.
  • CONCLUSIONS: MCV T antigen is generally not expressed in BCC or SCC tumors from a population favored to have MCV infection, ie, those persons already given the diagnosis of MCV-positive MCC.
  • This suggests that episodic polymerase chain reaction detection of MCV genome in BCC or SCC tumors may represent coincidental rather than causal infection, and that these tumors share other noninfectious risk factors.
  • [MeSH-major] Carcinoma, Basal Cell / virology. Carcinoma, Merkel Cell / virology. Carcinoma, Squamous Cell / virology. Immunocompetence. Skin Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20584559.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA120726; United States / NCI NIH HHS / CA / CA136363
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / DNA, Viral
  •  go-up   go-down


19. Leibeling D, Laspe P, Emmert S: Nucleotide excision repair and cancer. J Mol Histol; 2006 Sep;37(5-7):225-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NER consists of a multistep process in which the DNA lesion is recognized and demarcated by DNA unwinding.
  • XP patients show severe sun sensitivity, freckling in sun exposed skin, and develop skin cancers already during childhood.
  • Clinical symptoms of TTD patients include sun sensitivity, freckling in sun exposed skin areas, and brittle sulfur-deficient hair.
  • In contrast to XP patients, CS and TTD patients are not skin cancer prone.
  • Studying these syndromes can increase the knowledge of skin cancer development including cutaneous melanoma as well as basal and squamous cell carcinoma in general that may lead to new preventional and therapeutic anticancer strategies in the normal population.

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cells Tissues Organs. 2004;177(3):189-98 [15388993.001]
  • [Cites] Arch Dermatol. 1980 Dec;116(12):1375-84 [7458366.001]
  • [Cites] Skin Pharmacol. 1994;7(5):257-61 [8054207.001]
  • [Cites] EMBO J. 1999 Jun 15;18(12 ):3491-501 [10369688.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7260-4 [8346243.001]
  • [Cites] Photochem Photobiol. 1993 Sep;58(3):450-4 [8234481.001]
  • [Cites] Basic Life Sci. 1990;53:149-60 [2282032.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6090-5 [10339546.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81 [9950243.001]
  • [Cites] Mol Gen Genet. 1991 Aug;228(1-2):153-9 [1679524.001]
  • [Cites] Biochemistry. 1992 Jul 28;31(29):6794-800 [1637815.001]
  • [Cites] Exp Dermatol. 2003 Oct;12(5):529-36 [14705792.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Sep;4(9):721-31 [16928240.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1085-90 [15731165.001]
  • [Cites] Mol Cell Biol. 1995 Jan;15(1):290-7 [7799936.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:317-29 [7587084.001]
  • [Cites] Biochimie. 1999 Jan-Feb;81(1-2):15-25 [10214906.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1614-8 [8434025.001]
  • [Cites] J Invest Dermatol. 1996 Oct;107(4):647-53 [8823375.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1666-77 [8612591.001]
  • [Cites] Hautarzt. 2002 Mar;53(3):167-73 [11974587.001]
  • [Cites] Exp Dermatol. 1996 Jun;5(3):173-80 [8840158.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8658-63 [9238033.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Oct;72(10):4071-5 [172893.001]
  • [Cites] Br J Dermatol. 1993 Apr;128(4):384-7 [8494750.001]
  • [Cites] Am J Med Genet. 1992 Jan 1;42(1):68-84 [1308368.001]
  • [Cites] Am J Hum Genet. 2001 Aug;69(2):291-300 [11443545.001]
  • [Cites] J Invest Dermatol. 1994 Nov;103(5 Suppl):96S-101S [7963692.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):465-8 [9641488.001]
  • [Cites] Science. 1999 Dec 3;286(5446):1897-905 [10583946.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):815-20 [11773631.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3116-21 [9096355.001]
  • [Cites] Am J Hum Genet. 1998 Jan;62(1):77-85 [9443879.001]
  • [Cites] Eur J Hum Genet. 2005 Feb;13(2):253-5 [15494739.001]
  • [Cites] Mol Cell. 1999 Jan;3(1):33-42 [10024877.001]
  • [Cites] J Biol Chem. 1993 Oct 5;268(28):21293-300 [8407967.001]
  • [Cites] Biochimie. 1999 Jan-Feb;81(1-2):39-44 [10214908.001]
  • [Cites] J Cell Physiol. 2002 Apr;191(1):28-41 [11920679.001]
  • [Cites] Nature. 1993 May 13;363(6425):114-5 [8483493.001]
  • [Cites] J Invest Dermatol. 1998 Nov;111(5):791-6 [9804340.001]
  • [Cites] J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):329-35 [8294592.001]
  • [Cites] Science. 1997 Feb 14;275(5302):990-3 [9020084.001]
  • [Cites] Am J Med Genet A. 2004 Jul 30;128A(3):235-45 [15216543.001]
  • [Cites] Hum Mol Genet. 2001 Oct 15;10(22):2539-47 [11709541.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):505-9 [12663511.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):714-9 [15220921.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7570-3 [9065408.001]
  • [Cites] Clin Dermatol. 1985 Jan-Mar;3(1):33-69 [3833325.001]
  • [Cites] Neurology. 2000 Nov 28;55(10):1442-9 [11185579.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10103-9 [11124949.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):403-8 [11238179.001]
  • [Cites] Hum Genet. 1996 Apr;97(4):418-23 [8834235.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2151-6 [10681431.001]
  • [Cites] Nucleic Acids Res. 1992 Sep 25;20(18):4761-4 [1357629.001]
  • [Cites] Science. 1996 Jul 5;273(5271):63-7 [8658197.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):295-9 [11872635.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):241-50 [3545087.001]
  • [Cites] J Invest Dermatol. 1972 Mar;58(3):124-8 [5013606.001]
  • [Cites] Cancer Surv. 1985;4(3):601-24 [3916657.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2002 Jun;18(3):109-16 [12207672.001]
  • [Cites] JAMA. 1988 Jul 15;260(3):384-8 [3379749.001]
  • [Cites] Am J Hum Genet. 1993 Oct;53(4):817-21 [8213812.001]
  • [Cites] J Invest Dermatol. 1995 Jun;104(6):933-6 [7769261.001]
  • [Cites] Jpn J Cancer Res. 1987 Nov;78(11):1135-43 [3121549.001]
  • [Cites] Mol Med Today. 1999 Feb;5(2):86-94 [10200950.001]
  • [Cites] Nucleic Acids Res. 1993 Mar 11;21(5):1055-9 [8464692.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2001 Oct;17(5):203-12 [11555329.001]
  • [Cites] Hum Mol Genet. 1994 Jun;3(6):963-7 [7951246.001]
  • [Cites] Photochem Photobiol. 1998 Sep;68(3):243-56 [9747581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9463-8 [9256505.001]
  • [Cites] Mutat Res. 1991 Jul;255(1):1-9 [2067547.001]
  • [Cites] Photochem Photobiol. 1991 Nov;54(5):753-60 [1665912.001]
  • [Cites] Mutat Res. 1982 Dec;106(2):347-56 [6185841.001]
  • [Cites] Ann Intern Med. 1974 Feb;80(2):221-48 [4811796.001]
  • [Cites] Hum Genet. 1986 Oct;74(2):107-12 [3770739.001]
  • [Cites] Nat Genet. 1994 Jun;7(2):189-94 [7920640.001]
  • [Cites] Cell. 2000 Apr 14;101(2):159-71 [10786832.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1284-9 [11181991.001]
  • [Cites] Photochem Photobiol. 1989 Jun;49(6):805-19 [2672059.001]
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4227-31 [1638536.001]
  • [Cites] Science. 1992 Apr 24;256(5056):523-6 [1575827.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1790-5 [10660687.001]
  • [Cites] J Invest Dermatol. 1994 Apr;102(4):485-9 [8151125.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(22):9784-92 [16260596.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 19;95(4):308-15 [12591987.001]
  • [Cites] Nucleic Acids Res. 2001 Apr 1;29(7):1443-52 [11266544.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):972-82 [12060391.001]
  • [Cites] Science. 1999 Jul 9;285(5425):263-5 [10398605.001]
  • [Cites] Am J Hum Genet. 1997 Feb;60(2):320-9 [9012405.001]
  • [Cites] Nucleic Acids Res. 2002 Aug 15;30(16):3624-31 [12177305.001]
  • [Cites] J Invest Dermatol. 2000 Jan;114(1):34-9 [10620112.001]
  • [Cites] Brain. 1991 Jun;114 ( Pt 3):1335-61 [2065254.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4103-7 [8797573.001]
  • [Cites] Oncogene. 2000 Sep 28;19(41):4721-8 [11032022.001]
  • [Cites] J Natl Cancer Inst. 1979 Jun;62(6):1415-21 [286113.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):84-94 [16081512.001]
  • [Cites] Mol Cell Biol. 1991 Aug;11(8):4128-34 [1649389.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):15-23 [11156600.001]
  • [Cites] Methods Mol Biol. 1999;113:133-46 [10443416.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 1996 Jun;12(3):122-30 [8956362.001]
  • [Cites] J Invest Dermatol. 1994 Oct;103(4):461-8 [7930668.001]
  • [Cites] Am J Hum Genet. 2003 Dec;73(6):1217-39 [14639525.001]
  • [Cites] Cutis. 2004 Nov;74(5 Suppl):10-3 [15603216.001]
  • [Cites] Nature. 1999 Jun 17;399(6737):700-4 [10385124.001]
  • [Cites] J Virol. 1984 Dec;52(3):846-56 [6092716.001]
  • [Cites] J Am Acad Dermatol. 2001 Jun;44(6):891-920; quiz 921-4 [11369901.001]
  • [Cites] J Biol Chem. 1994 Dec 30;269(52):32709-12 [7806489.001]
  • [Cites] Ann Neurol. 1986 Jul;20(1):70-5 [3740815.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):926-9 [11289350.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):344-51 [11841555.001]
  • [Cites] Hum Genet. 1997 Dec;101(3):317-22 [9439661.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):453-60 [10688865.001]
  • [Cites] Nat Med. 2001 Aug;7(8):961-6 [11479630.001]
  • [Cites] Mutat Res. 1996 Feb 15;362(2):209-11 [8596540.001]
  • [Cites] Am J Hum Genet. 2000 Apr;66(4):1221-8 [10739753.001]
  • [Cites] Photochem Photobiol. 1996 Apr;63(4):356-7 [8934734.001]
  • [Cites] Nature. 2001 May 17;411(6835):366-74 [11357144.001]
  • [Cites] Curr Biol. 1999 Mar 11;9(5):273-6 [10074455.001]
  • [Cites] J Biol Chem. 1991 Nov 5;266(31):20940-5 [1939143.001]
  • (PMID = 16855787.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 150
  •  go-up   go-down


20. Wells MJ, Taylor RS: Mohs micrographic surgery for penoscrotal malignancy. Urol Clin North Am; 2010 Aug;37(3):403-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific penoscrotal neoplasias discussed in this article include invasive and in situ squamous cell carcinoma, basal cell carcinoma, extramammary Paget disease, and granular cell tumor.
  • [MeSH-minor] Carcinoma, Squamous Cell / surgery. Humans. Male. Paget Disease, Extramammary / surgery. Penile Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674695.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Chew YK, Noorizan Y, Khir A, Brito-Mutunayagam S, Prepagaran N: The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose. Med J Malaysia; 2008 Oct;63(4):339-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose.
  • Basal cell carcinoma (BCC) is an indolent, slow-growing malignant skin tumour.
  • The nose is a common site for malignant skin tumours, such as basal cell carcinoma and squamous cell carcinoma because it is exposed to the sun.
  • Excision of the BCC will leave the nose with a soft tissue defect which requires reconstruction.
  • This report illustrates a case of BCC of nose whereby a wide excision and reconstruction was performed with a paramedian forehead flap.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose Neoplasms / surgery. Rhinoplasty / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385500.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


22. Chen T, Bertenthal D, Sahay A, Sen S, Chren MM: Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch Dermatol; 2007 Nov;143(11):1386-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma.
  • OBJECTIVE: To identify predictors of skin-related quality of life (QOL) after treatment of nonmelanoma skin cancer (NMSC).
  • SETTING: University-affiliated private practice and a Veterans Affairs clinic.
  • MAIN OUTCOME MEASURE: Skin-related QOL, measured with the 16-item version of Skindex-16, a validated measure.
  • RESULTS: Controlling for treatment group, the strongest independent predictor of skin-related QOL after treatment of NMSC was pretreatment skin-related QOL.
  • No tumor or care characteristic (including location of tumor, size of tumor, site of therapy, or training level of treating clinician [attending physician, resident, or nurse practitioner]) was found to predict better skin-related QOL after treatment of NMSC.
  • CONCLUSIONS: Patients with better pretreatment skin-related QOL, less comorbidity, and better mental health status had better skin-related QOL after treatment of NMSC.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Quality of Life. Skin / physiopathology. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2007 Nov;143(11):1429-32 [18025368.001]
  • [ErratumIn] Arch Dermatol. 2008 Feb;144(2):230
  • (PMID = 18025362.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K02 AR02203; United States / NIAMS NIH HHS / AR / K24-AR052667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


23. Ouyang YH: Skin cancer of the head and neck. Semin Plast Surg; 2010 May;24(2):117-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer of the head and neck.
  • The majority of skin cancers of the head and neck are nonmelanoma skin cancers (NMSC).
  • Basal cell carcinoma and squamous cell carcinoma are the most frequent types of NMSC.
  • Malignant melanoma is an aggressive neoplasm of skin, and the ideal adjuvant therapy has not yet been found, although various options for treatment of skin cancer are available to the patient and physician, allowing high cure rate and excellent functional and cosmetic outcomes.
  • Sunscreen protection and early evaluation of suspicious areas remain the first line of defense against skin cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22550432.001).
  • [ISSN] 1535-2188
  • [Journal-full-title] Seminars in plastic surgery
  • [ISO-abbreviation] Semin Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3324239
  • [Keywords] NOTNLM ; Basal cell carcinoma / Mohs' micrographic surgery / melanoma / nonmelanoma skin cancer / squamous cell carcinoma
  •  go-up   go-down


24. Babilas P, Landthaler M, Szeimies RM: Photodynamic therapy in dermatology. Eur J Dermatol; 2006 Jul-Aug;16(4):340-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, topical photodynamic therapy (PDT) has received approval for the treatment of dermato-oncologic conditions like actinic keratoses, Bowen's disease, in-situ squamous cell carcinoma and basal cell carcinoma in many countries all over the world.
  • Due to the easy accessibility of skin to light activation, incoherent lamps or LED arrays are suitable for PDT.
  • Either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving inflammatory skin conditions are induced.
  • Treating superficial non-melanoma skin cancer, PDT has been shown to be highly efficient despite the low level of invasiveness.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Basal Cell / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935788.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 80
  •  go-up   go-down


25. Vaid M, Katiyar SK: Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). Int J Oncol; 2010 May;36(5):1053-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in life style over the past several decades including much of the time spent outdoors and the use of tanning devices for cosmetic purposes by individuals have led to an increase in the incidence of solar ultraviolet (UV) radiation-induced skin diseases including the risk of skin cancers.
  • Solar UV radiations are considered as the most prevalent environmental carcinogens, and chronic exposure of the skin to UV leads to squamous and basal cell carcinoma and melanoma in human population.
  • Silymarin is one of them and extensively studied for its skin photoprotective capabilities.
  • ), and has been shown to have chemopreventive effects against photocarcinogenesis in mouse tumor models.
  • Topical treatment of silymarin inhibited photocarcinogenesis in mice in terms of tumor incidence, tumor multiplicity and growth of the tumors.
  • It is suggested that silymarin may favorably supplement sunscreen protection, and may be useful for skin diseases associated with solar UV radiation-induced inflammation, oxidative stress and immunomodulatory effects.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1993 Apr 23;260(5107):496-7 [8097337.001]
  • [Cites] Science. 1993 Apr 23;260(5107):547-9 [8097338.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):846-8 [8388060.001]
  • [Cites] Immunol Today. 1993 Jul;14(7):335-8 [8103338.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] Photochem Photobiol. 1993 Dec;58(6):813-7 [8310001.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Carcinogenesis. 1994 Jun;15(6):1099-103 [8020140.001]
  • [Cites] J Invest Dermatol. 1994 Aug;103(2):211-6 [8040612.001]
  • [Cites] J Leukoc Biol. 1994 Dec;56(6):769-75 [7996051.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):170-5 [7857113.001]
  • [Cites] J Immunol. 1995 May 15;154(10):5114-20 [7730617.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):4661-8 [7594465.001]
  • [Cites] Photochem Photobiol. 1995 Nov;62(5):855-61 [8570723.001]
  • [Cites] J Cell Biol. 1996 Apr;133(1):211-20 [8601609.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8285-94 [8626523.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1023-30 [8640756.001]
  • [Cites] J Invest Dermatol. 1996 Jun;106(6):1187-91 [8752655.001]
  • [Cites] Photochem Photobiol. 1996 Apr;63(4):356-7 [8934734.001]
  • [Cites] Photochem Photobiol. 1996 Apr;63(4):380-3 [8934743.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5254-61 [8955170.001]
  • [Cites] J Natl Cancer Inst. 1997 Apr 16;89(8):556-66 [9106644.001]
  • [Cites] Int J Oncol. 2002 Dec;21(6):1213-22 [12429970.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):927-36 [12771038.001]
  • [Cites] Carcinogenesis. 2003 Aug;24(8):1379-88 [12807737.001]
  • [Cites] J Invest Dermatol. 2003 Oct;121(4):862-8 [14632206.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):510-7 [15009738.001]
  • [Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 1):681-6 [9591810.001]
  • [Cites] J Cell Biochem Suppl. 1997;27:59-67 [9591194.001]
  • [Cites] J Invest Dermatol. 1998 Jun;110(6):966-71 [9620307.001]
  • [Cites] Br J Dermatol. 1998 Jul;139(1):3-10 [9764141.001]
  • [Cites] J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):611-25 [9777769.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):622-32 [9973210.001]
  • [Cites] Nat Med. 1999 Apr;5(4):418-22 [10202931.001]
  • [Cites] Br J Dermatol. 1999 Feb;140(2):255-8 [10233218.001]
  • [Cites] J Invest Dermatol. 1999 May;112(5):751-6 [10233767.001]
  • [Cites] J Am Acad Dermatol. 1999 May;40(5 Pt 1):697-701 [10321596.001]
  • [Cites] Am J Health Syst Pharm. 1999 Jun 15;56(12):1195-7 [10484652.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1404-13 [15831527.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1660-8 [16891451.001]
  • [Cites] J Dermatol Sci. 2007 Apr;46(1):21-30 [17289350.001]
  • [Cites] J Dermatol Sci. 2007 Dec;48(3):213-24 [17689055.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):266-71 [18221354.001]
  • [Cites] J Invest Dermatol. 2009 May;129(5):1258-70 [19020550.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Feb;3(2):179-89 [20103727.001]
  • [Cites] J Exp Med. 1998 Apr 6;187(7):1133-8 [9529329.001]
  • [Cites] J Investig Dermatol Symp Proc. 1999 Sep;4(1):97-100 [10537017.001]
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2117-24 [10545414.001]
  • [Cites] Cancer Lett. 1999 Dec 1;147(1-2):77-84 [10660092.001]
  • [Cites] Int Urol Nephrol. 1999;31(4):417-22 [10668934.001]
  • [Cites] J Heart Lung Transplant. 2000 Mar;19(3):249-55 [10713249.001]
  • [Cites] Liver Transpl. 2000 May;6(3):253-62 [10827224.001]
  • [Cites] Carcinogenesis. 2001 Feb;22(2):287-94 [11181450.001]
  • [Cites] Int J Oncol. 2001 Jun;18(6):1307-13 [11351267.001]
  • [Cites] J Leukoc Biol. 2001 May;69(5):719-26 [11358979.001]
  • [Cites] Photochem Photobiol. 2001 Jun;73(6):600-4 [11421064.001]
  • [Cites] Photochem Photobiol. 2001 Jun;73(6):621-9 [11421067.001]
  • [Cites] J Invest Dermatol. 2001 Jul;117(1):147-50 [11442762.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Oct 15;176(2):110-7 [11601887.001]
  • [Cites] Drugs. 2001;61(14):2035-63 [11735632.001]
  • [Cites] Photochem Photobiol. 2001 Dec;74(6):787-93 [11783934.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):314-46 [11839647.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):499-510 [11895866.001]
  • [Cites] Sci STKE. 2003 Jan 28;2003(167):RE2 [12554854.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6349-56 [15342425.001]
  • [Cites] Arzneimittelforschung. 1968 Jun;18(6):688-96 [5755805.001]
  • [Cites] Arzneimittelforschung. 1974 Apr;24(4):466-71 [4408125.001]
  • [Cites] J Natl Cancer Inst. 1974 Nov;53(5):1333-6 [4139281.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Dec;74(12):5574-8 [271984.001]
  • [Cites] Br J Clin Pharmacol. 1978 May;5(5):431-6 [656282.001]
  • [Cites] J Immunol. 1980 Jan;124(1):445-53 [6153101.001]
  • [Cites] Br Med J. 1979 Dec 8;2(6203):1461-6 [393355.001]
  • [Cites] Scand J Gastroenterol. 1982 Jun;17(4):517-21 [6753109.001]
  • [Cites] Science. 1983 Sep 23;221(4617):1256-64 [6351251.001]
  • [Cites] Immunol Rev. 1984 Aug;80:87-102 [6237978.001]
  • [Cites] Cancer Res. 1986 May;46(5):2203-7 [3516380.001]
  • [Cites] J Hepatol. 1989 Jul;9(1):105-13 [2671116.001]
  • [Cites] J Exp Med. 1989 Oct 1;170(4):1117-31 [2529340.001]
  • [Cites] Semin Dermatol. 1990 Mar;9(1):25-31 [2203440.001]
  • [Cites] J Invest Dermatol. 1990 Oct;95(4):436-40 [2120354.001]
  • [Cites] J Invest Dermatol. 1990 Nov;95(5):530-6 [2230216.001]
  • [Cites] Pharm Res. 1991 Feb;8(2):273-7 [1902564.001]
  • [Cites] Dermatol Clin. 1991 Oct;9(4):751-5 [1934649.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7516-20 [1502162.001]
  • [Cites] J Exp Med. 1993 Apr 1;177(4):1199-204 [8096238.001]
  • (PMID = 20372777.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA105368-01; United States / NCI NIH HHS / CA / R03 CA105368; United States / NCI NIH HHS / CA / R03 CA105368-02; United States / NCI NIH HHS / CA / CA105368-02; United States / NCI NIH HHS / CA / CA105368-01; United States / NCI NIH HHS / CA / CA105368
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antioxidants; 0 / Carcinogens; 0 / Plant Extracts; 0 / Silymarin
  • [Other-IDs] NLM/ NIHMS184206; NLM/ PMC2852174
  •  go-up   go-down


26. Geist DE, Garcia-Moliner M, Fitzek MM, Cho H, Rogers GS: Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg; 2008 Dec;34(12):1642-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management.
  • BACKGROUND: Perineural invasion (PNI) by cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) is an infrequent but not rare complication of traditionally low-morbidity skin cancers that can lead to catastrophic sequelae; 2.5% to 14% of CSCC and approximately 3% of BCC exhibit PNI.
  • MATERIALS AND METHODS: Cases of PNI treated with MMS and radiotherapy were reviewed for recurrence, disease-free follow-up, and adverse events.
  • When managing superficial skin tumors with PNI, a multidisciplinary team including a cutaneous surgeon and a radiation oncologist familiar with PNI is recommended.
  • [MeSH-major] Bell Palsy / etiology. Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / therapy. Skin Neoplasms / complications. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Mohs Surgery. Neoplasm Invasiveness. Peripheral Nerves

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bell's Palsy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018830.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Varga E, Kiss M, Szabó K, Kemény L: Detection of Merkel cell polyomavirus DNA in Merkel cell carcinomas. Br J Dermatol; 2009 Oct;161(4):930-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Merkel cell polyomavirus DNA in Merkel cell carcinomas.
  • BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive tumour for which an increasing incidence has been reported.
  • A new human polyomavirus, Merkel cell polyomavirus (MCV), was recently isolated from these tumours by applying digital transcriptome subtraction methodology.
  • METHODS: Nine primary or recurrent MCCs from seven patients were examined; 29 other tumours (squamous cell, basal cell and basosquamous carcinomas and malignant melanomas) were examined for comparative purposes.
  • [MeSH-major] Antigens, Viral, Tumor / genetics. Capsid Proteins / genetics. Carcinoma, Merkel Cell / virology. Polyomaviridae / genetics. Polyomavirus Infections / virology. Skin Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438857.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / Capsid Proteins
  •  go-up   go-down


28. Hatina J, Ruzicka T: [Relevance of cell culture models in cutaneous tumour biology. Part I: tumour cell lines]. Hautarzt; 2008 Jan;59(1):36-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relevance of cell culture models in cutaneous tumour biology. Part I: tumour cell lines].
  • [Transliterated title] Stellenwert der Zellkulturmodelle in kutaner Tumorbiologie. Teil I: Zelllinien tumorigen transformierter Zellen.
  • Cutaneous squamous cell carcinoma, basal cell carcinoma and melanoma, much like all other human solid tumors, result from a multi-step process in which genetic and epigenetic changes accumulate in the affected cells.
  • Cell culture models are a very valuable experimental system.
  • Tumor cell lines display similar functional hierarchy as tumors or tissues in vivo and can, consequently, provide a crucial source of minor cell subsets, like tumor stem cells.
  • Progression series of clonally related cell lines offer the opportunity to follow the process of sequential acquisition of transformation-related traits up to the development of properties with direct clinical equivalents, like tumorigenicity and metastatic competence.
  • While for most studies, human transformed cell lines are the model of choice, there are questions for which animal cell lines are strongly preferred, such as interactions between the tumor and the immune system.
  • To properly interpret the results of all experiments with classical two-dimensional cell culture, a possible danger of artifacts due to grossly unnatural environment must be constantly taken into account.
  • [MeSH-major] Cell Line, Tumor / pathology. Cell Line, Tumor / physiology. Disease Models, Animal. Skin Neoplasms / pathology. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Jan 8;23(1):30-8 [14712208.001]
  • [Cites] Annu Rev Pathol. 2007;2:175-89 [18039097.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):441-52 [10433937.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):159-67 [10623663.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:151-61 [12814947.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 15;142(2):87-91 [12699882.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7147-57 [14612508.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4359-70 [9494534.001]
  • [Cites] Mol Carcinog. 1998 Nov;23(3):144-58 [9833775.001]
  • [Cites] J Surg Res. 1995 Feb;58(2):165-74 [7861768.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3075-86 [8674065.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2296-302 [2156614.001]
  • [Cites] J Cell Biochem. 1994 Feb;54(2):161-73 [8175891.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Exp Dermatol. 2007 Apr;16(4):297-301 [17359335.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):365-78 [14973382.001]
  • [Cites] Exp Dermatol. 2000 Apr;9(2):104-17 [10772384.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1567-79 [11583982.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:339-73 [16824012.001]
  • [Cites] Arch Dermatol. 1996 Oct;132(10):1185-93 [8859029.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1372-7 [16470173.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4320-33 [15899824.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):1026-36 [12821146.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5670-6 [4053039.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):401-4 [15675960.001]
  • [Cites] Exp Cell Res. 2000 Aug 1;258(2):352-60 [10896786.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):935-46 [17320377.001]
  • [Cites] J Dtsch Dermatol Ges. 2005 Jul;3(7):493-503 [15967008.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2205-11 [2009539.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2840-7 [2183932.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):875-9 [8631027.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Aug;132(31-32):1629-32 [17654417.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1214-6 [16702970.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3759-65 [12097286.001]
  • [Cites] Cancer Res. 1980 May;40(5):1636-44 [7370995.001]
  • [Cites] Histol Histopathol. 2002;17 (3):951-9 [12168807.001]
  • [Cites] J Invest Dermatol. 2000 Dec;115(6):1095-103 [11121147.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S35-42 [9578415.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3837-44 [12881305.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):457-65 [15675968.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3112-7 [8674069.001]
  • [Cites] Prostate. 1986;9(3):261-81 [3774632.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]
  • [Cites] Schweiz Med Wochenschr. 2000 Apr 29;130(17):617-24 [10829299.001]
  • [Cites] Hautarzt. 2004 Oct;55(10):942-51 [15349693.001]
  • [Cites] Pathologe. 1994 Jun;15(3):141-9 [8072948.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):976-81 [12439909.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):668-75 [7532159.001]
  • [Cites] Nat Med. 1997 Jul;3(7):788-92 [9212109.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • (PMID = 18058078.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 64
  •  go-up   go-down


29. Love WE, Bernhard JD, Bordeaux JS: Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol; 2009 Dec;145(12):1431-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
  • OBJECTIVES: To conduct a systematic review to determine clearance rates and adverse effects of topical imiquimod or fluorouracil therapy in the treatment of nonmelanoma skin cancers such as basal (BCC) and squamous cell carcinoma (SCC), and to develop recommendations for the use of topical imiquimod or fluorouracil to treat BCC and SCC.
  • STUDY SELECTION: Prospective, retrospective, and case studies in English containing a minimum of 4 subjects and a 6-month follow-up or posttreatment histologic evaluation.
  • DATA EXTRACTION: We calculated the rate of clearance and adverse effects for BCC subtypes and invasive and in situ SCC treated with topical imiquimod or fluorouracil.
  • Imiquimod use produced the following clearance rates: 43% to 100% for superficial BCC, 42% to 100% for nodular BCC, 56% to 63% for infiltrative BCC, 73% to 88% for SCC in situ, and 71% for invasive SCC.
  • Fluorouracil use produced the following clearance rates: 90% for superficial BCC and 27% to 85% for SCC in situ.
  • CONCLUSIONS: Evidence supports the use of topical imiquimod as monotherapy for superficial BCC and topical fluorouracil as monotherapy for superficial BCC and SCC in situ.
  • [MeSH-major] Aminoquinolines / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Fluorouracil / pharmacokinetics. Skin Neoplasms / drug therapy


30. Ishihara K: [Reasons for the increased incidence of skin cancer]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1380-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reasons for the increased incidence of skin cancer].
  • The cutaneous malignancies with an increasing incidence in Japan are squamous cell carcinoma, basal cell carcinoma, and malignant melanoma.
  • According to a nationwide questionnaire survey (responses from 94 centers), basal cell carcinoma has the highest incidence and accounts for nearly 50% of all skin malignancies, followed by squamous cell carcinoma (31%) and malignant melanoma (21%).
  • The number of cases of each tumor has grown annually, and comparison of the percent increases between 1987 and 2001 shows an increase of about 1.5-fold for basal cell carcinoma or 1.7-fold for squamous cell carcinoma or malignant melanoma.
  • Supported by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare, the Malignant Skin Tumor Research Group has been investigating the factors behind these increases by detailed statistical analysis of data obtained from 1987 onwards from designated centers (19-22 centers).
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033224.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M: Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev; 2010 Nov;19(11):2942-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photosensitizing medication use and risk of skin cancer.
  • Whether use of these medications affects skin cancer risk, however, is unclear.
  • METHODS: Using a cohort of all Danish residents ≥15 years old in 1995 to 2006 (n = 4,761,749) and information from Danish national registers, we examined associations between use of photosensitizing medications and risk of basal cell carcinoma, cutaneous malignant melanoma, Merkel cell carcinoma, and squamous cell carcinoma.
  • RESULTS: Users of only 2 of 19 medications for long-term use (methyldopa and furosemide) had both a ≥20% increased risk of skin cancer (compared with nonusers) and an increase in risk with increasing duration of use; these effects were limited to basal cell carcinoma and squamous cell carcinoma, respectively.
  • In contrast, 8 of 10 medications for short-term use were associated with both a ≥20% increased risk of skin cancer and an increase in risk with increasing use for at least one of the four cancers.
  • CONCLUSION: We found little evidence of an increased risk of skin cancer among users of photosensitizing medications for long-term daily use, but could not rule out the possibility that users of some photosensitizing medications for short-term use may have an increased risk of skin cancer.
  • Our study examined the effect of a wide range of photosensitizing medications on skin cancer risk and suggests that future work should focus on photosensitizing medications for short-term use.
  • [MeSH-major] Photosensitivity Disorders / chemically induced. Prescription Drugs / adverse effects. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20861398.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prescription Drugs
  •  go-up   go-down


32. Al-Arashi MY, Salomatina E, Yaroslavsky AN: Multimodal confocal microscopy for diagnosing nonmelanoma skin cancers. Lasers Surg Med; 2007 Oct;39(9):696-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal confocal microscopy for diagnosing nonmelanoma skin cancers.
  • BACKGROUND AND SIGNIFICANCE: The standard diagnostic procedure for skin cancers is invasive biopsy followed by histopathological evaluation.
  • In this study, the suitability of dye-enhanced multimodal confocal microscopy for the detection of nonmelanoma skin cancers was evaluated.
  • MATERIALS AND METHODS: For the experiments we used fresh tumor material stained using 0.2 mg/ml or 0.05 mg/ml aqueous solutions of methylene blue (MB) or toluidine blue (TB), respectively.
  • Reflectance, fluorescence, and fluorescence polarization images of skin specimens stained with MB and TB were excited by 656 nm and 633 nm light, respectively.
  • In total we imaged, analyzed, and compared to histology at least 10 samples of each tumor-type including nodular basal cell carcinoma (BCC), infiltrative basal cell carcinoma, and squamous cell carcinoma (SCC).
  • RESULTS AND CONCLUSION: The morphological features and appearance of skin structures in the fluorescence images correlate well with corresponding histology for all investigated tumor-types.
  • Our results indicate the feasibility of using multimodal confocal microscopy as real-time tool for detecting skin pathology.
  • [MeSH-major] Microscopy, Confocal. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Coloring Agents. Diagnosis, Differential. Equipment Design. Humans. In Vitro Techniques. Methylene Blue. Staining and Labeling. Tolonium Chloride

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17960751.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 15XUH0X66N / Tolonium Chloride; T42P99266K / Methylene Blue
  •  go-up   go-down


33. Ezzedine K, Latreille J, Kesse-Guyot E, Galan P, Hercberg S, Guinot C, Malvy D: Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation. Eur J Cancer; 2010 Dec;46(18):3316-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation.
  • CONTEXT: In the SU.VI.MAX study, antioxidant supplementation for 7.5 years was found to increase skin cancer risk in women but not in men.
  • OBJECTIVE: To investigate the potential residual or delayed effect of antioxidant supplementation on skin cancer incidence after a 5-year post-intervention follow-up.
  • DESIGN, SETTING AND PARTICIPANTS: Assessment of skin cancer including melanoma and non-melanoma during the post-intervention follow-up (September 2002-August 2007).
  • MAIN OUTCOME MEASURES: Total skin cancer incidence, including melanoma, squamous cell carcinoma and basal cell carcinoma.
  • Six squamous cell carcinomas were found in women and 15 in men (10 and 25, respectively, for the total period).
  • Finally, 40 basal cell carcinomas appeared in women and 36 in men (98 and 94, respectively, for the total period).
  • No delayed effects, either on melanoma or non-melanoma skin cancers, were observed for either gender.
  • CONCLUSIONS: The risk of skin cancers associated with antioxidant intake declines following interruption of supplementation.
  • This supports a causative role for antioxidants in the evolution of skin cancers.
  • [MeSH-major] Antioxidants / adverse effects. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Vitamins / adverse effects

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20605091.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00272428
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Vitamins
  •  go-up   go-down


34. Benbenisty KM, Andea A, Metcalf J, Cook J: Atypical cellular neurothekeoma treated with Mohs micrographic surgery. Dermatol Surg; 2006 Apr;32(4):582-7; discussion 587
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Atypical cellular neurothekeoma is a rare neoplasm generally regarded as a benign tumor with locally aggressive behavior.
  • Recurrence is common with inadequate excision, but metastatic disease has yet to be reported.
  • RESULTS: The neoplasm was extirpated in a three-stage, five section Mohs surgery procedure.
  • CONCLUSION: Mohs micrographic surgery is unsurpassed in its efficacy in treating a wide variety of nonmelanoma skin cancers.
  • Although most commonly used to address basal and squamous cell carcinoma, it has also been reported as a successful treatment for melanoma and a wide variety of cutaneous malignancies.
  • Debate in the literature is ongoing regarding the true histogenesis of this rare tumor.
  • Because of this tumor's local destructive behavior and propensity to recur with inadequate resection, we recommend Moths micrographic surgery for the treatment of cellular neurothekeomas.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2008 Mar;34(3):428 [18248473.001]
  • (PMID = 16681671.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


35. Honeycutt KA, Waikel RL, Koster MI, Wang XJ, Roop DR: The effect of c-myc on stem cell fate influences skin tumor phenotype. Mol Carcinog; 2010 Apr;49(4):315-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of c-myc on stem cell fate influences skin tumor phenotype.
  • Nonmelanoma skin cancers (NMSCs) consist of a variety of tumor types including basal cell carcinoma, squamous cell carcinoma, a variety of hair follicle tumors, and sebaceous gland tumors.
  • Our goal in the current study was to determine if alterations in the commitment of multipotent stem cells to different cell fates would influence tumor phenotype.
  • [MeSH-major] Proto-Oncogene Proteins c-myc / genetics. Skin Neoplasms / genetics. Skin Neoplasms / pathology. Stem Cells / pathology
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma, Sebaceous / pathology. Animals. Carcinogens / toxicity. Cell Differentiation / genetics. Cell Lineage / genetics. Crosses, Genetic. Female. Heterozygote. Male. Mice. Mice, Inbred ICR. Mice, Inbred Strains. Mice, Transgenic. Multipotent Stem Cells / pathology. Papilloma / pathology. Phenotype. Sebaceous Gland Neoplasms / pathology. Tetradecanoylphorbol Acetate / pharmacology. Transgenes

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146250.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR47898; United States / NCI NIH HHS / CA / CA09197; United States / NCI NIH HHS / CA / CA105491; United States / NCI NIH HHS / CA / CA52607; United States / NCI NIH HHS / CA / CA79998
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Proto-Oncogene Proteins c-myc; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


36. Watkins J: Dermatology and the community nurse: actinic (solar) keratosis. Br J Community Nurs; 2010 Jan;15(1):6, 8, 10-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are then able to check other sun-exposed areas such as the face, ears, scalp, back and limbs to discover any other lesions or more serious problems of basal cell carcinoma, squamous cell carcinoma or malignant melanoma the would require referral, sometimes urgently, to a dermatologist for full assessment and treatment.
  • [MeSH-major] Keratosis / nursing. Skin Neoplasms / nursing. Sunlight / adverse effects
  • [MeSH-minor] Community Health Nursing. Diagnosis, Differential. Humans. Nursing Diagnosis. Protective Clothing. Risk Factors. Sunscreening Agents

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216512.001).
  • [ISSN] 1462-4753
  • [Journal-full-title] British journal of community nursing
  • [ISO-abbreviation] Br J Community Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sunscreening Agents
  • [Number-of-references] 13
  •  go-up   go-down


37. Dawe RS: Treatment options for non-melanoma skin cancer. G Ital Dermatol Venereol; 2009 Aug;144(4):453-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for non-melanoma skin cancer.
  • Non melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) are becoming more common.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755949.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 38
  •  go-up   go-down


38. Ross AH, Kennedy CT, Collins C, Harrad RA: The use of imiquimod in the treatment of periocular tumours. Orbit; 2010 Apr;29(2):83-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients were diagnosed with basal cell carcinoma of the eyelid, one patient with actinic keratosis, one with intraepidermal squamous cell carcinoma (Bowen's disease) and one patient had concomitant squamous cell carcinoma and intraepidermal squamous cell carcinoma.
  • In our experience, it is a safe and effective treatment for periocular lesions, including actinic keratosis, intraepidermal squamous cell carcinoma, basal cell carcinoma and squamous cell carcinoma.
  • To our knowledge, this is the first published description of the successful use of 5% Imiquimod in treating moderately differentiated squamous cell carcinoma of the eyelid.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Eyelid Neoplasms / drug therapy. Keratosis, Actinic / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Bowen's Disease / drug therapy. Bowen's Disease / pathology. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Ophthalmic Solutions. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394545.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ophthalmic Solutions; 99011-02-6 / imiquimod
  •  go-up   go-down


39. Wilkins K, Dolev JC, Turner R, LeBoit PE, Berger TG, Maurer TA: Approach to the treatment of cutaneous malignancy in HIV-infected patients. Dermatol Ther; 2005 Jan-Feb;18(1):77-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients infected with human immunodeficiency virus (HIV) have an increased risk of developing skin cancers.
  • This article will review and discuss management issues for the following malignancies: lymphomas, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, and Kaposi's sarcoma.
  • [MeSH-major] HIV Infections / complications. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / therapy. Melanoma / complications. Melanoma / diagnosis. Melanoma / therapy. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842615.001).
  • [ISSN] 1396-0296
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 148
  •  go-up   go-down


40. Beljaards RC, Kirtschig G, Boorsma DM: Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma. Dermatol Surg; 2008 Nov;34(11):1577-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma.
  • [MeSH-major] Antigens, CD56 / biosynthesis. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798745.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


41. Dotto J, Pelosi G, Rosai J: Expression of p63 in thymomas and normal thymus. Am J Clin Pathol; 2007 Mar;127(3):415-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The DeltaN-p63 isoforms of p63, which are believed to behave as oncogenes, are expressed in squamous cell carcinoma, basal cell carcinoma, and transitional cell carcinoma.
  • We studied 66 cases of thymoma (1 type A, 8 type AB, 12 type B1, 19 type B2, 12 type B3, and 14 type C/thymic carcinoma) and 10 specimens of normal human thymus arranged in tissue microarrays.
  • All thymomas (including thymic carcinomas) were positive for p63 regardless of type.
  • [MeSH-major] DNA-Binding Proteins / biosynthesis. Thymoma / metabolism. Thymus Gland / chemistry. Thymus Neoplasms / metabolism. Trans-Activators / biosynthesis. Tumor Suppressor Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276940.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


42. Szeimies RM, Morton CA, Sidoroff A, Braathen LR: Photodynamic therapy for non-melanoma skin cancer. Acta Derm Venereol; 2005;85(6):483-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for non-melanoma skin cancer.
  • Photodynamic therapy is a treatment modality that has been shown to be effective mainly for the dermato-oncologic conditions: actinic keratosis, Bowen's disease, in situ squamous cell carcinoma and basal cell carcinoma.
  • For actinic keratosis and basal cell carcinoma, methyl aminolevulinate-photodynamic therapy is already approved in Europe, Australia and New Zealand, and is now also approved for actinic keratosis in the US.
  • [MeSH-major] Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Humans. Photosensitizing Agents

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396794.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 51
  •  go-up   go-down


43. Altan-Yaycioglu R, Canan H, Sizmaz S, Bal N, Pelit A, Akova YA: Nasolacrimal duct obstruction: clinicopathologic analysis of 205 cases. Orbit; 2010 Oct;29(5):254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only one patient had the diagnosis of chronic leukemia, others had no preexisting history of systemic disease.
  • Three patients had abnormal pathology: Lymphoproliferative disease in the patient with chronic leukemia, granulomatous inflammation, and basosquamous cell carcinoma.
  • Even though rare, malignant or systemic disease in patients with neither specific history nor clinical or radiological finding might be observed in these cases.
  • Thus, we recommend taking biopsy if any suspicion of abnormality of the lacrimal sac exists.
  • [MeSH-major] Lacrimal Duct Obstruction / diagnosis. Nasolacrimal Duct / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Child. Dacryocystorhinostomy. Female. Humans. Lacrimal Apparatus Diseases / diagnosis. Male. Middle Aged. Prospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704489.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Payette MJ, Whalen J, Grant-Kels JM: Nutrition and nonmelanoma skin cancers. Clin Dermatol; 2010 Nov-Dec;28(6):650-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutrition and nonmelanoma skin cancers.
  • The incidence of nonmelanoma skin cancer is increasing every year.
  • Basal cell carcinoma and squamous cell carcinoma are the two major types of nonmelanoma skin cancer.
  • Among other factors, understanding the potential role of nutrients in the development, progression, and treatment of nonmelanoma skin cancer is critical.
  • This contribution provides a review of the nutrients that have been more extensively investigated in the literature with regard to nonmelanoma skin cancer, including dietary fats, retinol, carotenoids, vitamin C, vitamin D, vitamin E, selenium, copper, iron, zinc, green tea, and black tea.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Diet. Micronutrients / administration & dosage. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • Hazardous Substances Data Bank. VITAMIN A .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21034989.001).
  • [ISSN] 1879-1131
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Micronutrients; 0 / Tea; 11103-57-4 / Vitamin A; 1406-16-2 / Vitamin D; 1406-18-4 / Vitamin E; 36-88-4 / Carotenoids; 789U1901C5 / Copper; E1UOL152H7 / Iron; H6241UJ22B / Selenium; J41CSQ7QDS / Zinc; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


45. Stollery N: Basal and squamous cell carcinoma. Practitioner; 2006 Dec;250(1689):46, 48-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal and squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Psoriasis / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eyelid Neoplasms / diagnosis. Humans

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283757.001).
  • [ISSN] 0032-6518
  • [Journal-full-title] The Practitioner
  • [ISO-abbreviation] Practitioner
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  •  go-up   go-down


46. Fekecs T, Kádár Z, Battyáni Z, Kalmár-Nagy K, Szakály P, Horváth OP, Wéber G, Ferencz A: Incidence of nonmelanoma skin cancer after human organ transplantation: single-center experience in Hungary. Transplant Proc; 2010 Jul-Aug;42(6):2333-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of nonmelanoma skin cancer after human organ transplantation: single-center experience in Hungary.
  • There is increasing evidence that nonmelanoma skin cancers (NMSCs) are the most frequently observed tumors in transplant recipients.
  • All patients underwent a full skin examination for NMSC, and completed a standardized questionnaire.
  • Histologic analysis verified 13 basal cell carcinomas and 3 squamous cell carcinomas (ratio, 4:1).
  • These data indicate the relevance of skin cancer surveillance in transplant recipients.
  • Our results correspond to international statistics except for the ratio of basal cell carcinoma to squamous cell carcinoma.
  • [MeSH-major] Organ Transplantation / adverse effects. Skin Neoplasms / epidemiology
  • [MeSH-minor] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Female. Follow-Up Studies. Humans. Hungary / epidemiology. Kidney Transplantation / adverse effects. Male. Middle Aged. Pancreas Transplantation / adverse effects. Skin / pathology. Surveys and Questionnaires. Time Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20692474.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Marcet S: Atypical fibroxanthoma/malignant fibrous histiocytoma. Dermatol Ther; 2008 Nov-Dec;21(6):424-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical fibroxanthoma/malignant fibrous histiocytoma.
  • Atypical fibroxanthoma (AFX) is an unusual spindle cell tumor occurring on actinically damaged skin of the head and neck.
  • Clinically, it is often confused with basal cell carcinoma, squamous cell carcinoma, or even melanoma.
  • Although initially thought to be a diagnosis of exclusion histologically, newer immunostains have helped in the identification of AFX.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Histiocytoma, Malignant Fibrous / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Mohs Surgery. Neoplasm Recurrence, Local


48. Johansen P, Berg K, Selbo PK, Hofbauer GF: [Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer]. Praxis (Bern 1994); 2010 Nov 17;99(23):1423-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer].
  • [Transliterated title] Photochemische Internalisierung (PCI): eine Weiterentwicklung der photodynamischen Therapie zur Behandlung von Hautkrebs.
  • Recently, several new and non-invasive methods have been introduced for the treatment of skin cancers.
  • Topical creams using the immune modulator imiquimod or the COX inhibitor diclofenac (with hyaluronic acid) are now registered for use against neoplasms such as basal or squamous cell carcinoma.
  • A refined version of PDT, namely photochemical internalisation, is currently subject to a first clinical trial in patients with osteosarcoma, squamous cell carcinoma, head and neck cancer as well as adenocarcinoma of the breast.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Melanoma / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Cytosol / drug effects. Endocytosis. Endosomes / drug effects. Humans. Melanoma, Experimental / drug therapy. Mice. Neoplasm Transplantation


49. Moan J, Porojnicu AC, Dahlback A: Ultraviolet radiation and malignant melanoma. Adv Exp Med Biol; 2008;624:104-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet radiation and malignant melanoma.
  • Essential features of the epidemiology and photobiology of cutaneous malignant melanoma (CMM) in Norway were studied in comparison with data from countries at lower latitudes.
  • This hypothesis was supported both by latitude gradients, by time trends and by changing patterns of tumor density on different body localizations.
  • Comparisons of skin cancer data from Norway and Australia/New Zealand indicate that squamous cell carcinoma and basal cell carcinoma are mainly related to annual solar UVB fluences, while UVA fluences play a larger role for CMM.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348451.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


50. Abdel-Malek ZA, Kadekaro AL, Swope VB: Stepping up melanocytes to the challenge of UV exposure. Pigment Cell Melanoma Res; 2010 Apr;23(2):171-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to solar ultraviolet radiation (UV) is the main etiological factor for skin cancer, including melanoma.
  • Therefore, maintaining genomic stability of melanocytes is crucial for prevention of melanoma, as well as keratinocyte-derived basal and squamous cell carcinoma.
  • The response of melanocytes to UV is mediated mainly by a network of paracrine factors that not only activate melanogenesis, but also DNA repair, anti-oxidant, and survival pathways that are pivotal for maintenance of genomic stability and prevention of malignant transformation or apoptosis.
  • Unraveling these mechanisms might lead to strategies to prevent melanoma, as well as non-melanoma skin cancer.
  • [MeSH-major] DNA Repair / physiology. Genomic Instability. Melanocytes / metabolism. Melanoma / metabolism. Skin Neoplasms / metabolism. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pigment Cell Melanoma Res. 2011 Apr;24(2):265-7 [21513010.001]
  • (PMID = 20128873.001).
  • [ISSN] 1755-148X
  • [Journal-full-title] Pigment cell & melanoma research
  • [ISO-abbreviation] Pigment Cell Melanoma Res
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30-ES006096; United States / NCI NIH HHS / CA / R01CA114095; United States / NIEHS NIH HHS / ES / R01ES009110; United States / NIEHS NIH HHS / ES / R01ES017561
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Number-of-references] 197
  •  go-up   go-down


51. Fabbrocini G, Triassi M, Mauriello MC, Torre G, Annunziata MC, De Vita V, Pastore F, D'Arco V, Monfrecola G: Epidemiology of skin cancer: role of some environmental factors. Cancers (Basel); 2010;2(4):1980-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of skin cancer: role of some environmental factors.
  • The incidence rate of melanoma and non-melanoma skin cancer entities is dramatically increasing worldwide.
  • Exposure to UVB radiation is known to induce basal and squamous cell skin cancer in a dose-dependent way and the depletion of stratospheric ozone has implications for increases in biologically damaging solar UVB radiation reaching the earth's surface.
  • In humans, arsenic is known to cause cancer of the skin, as well as cancer of the lung, bladder, liver, and kidney.
  • SCC and BCC (squamous and basal cell carcinoma) have been reported to be associated with ingestion of arsenic alone or in combination with other risk factors.
  • Higher temperatures accompanying climate change may lead, among many other effects, to increasing incidence of skin cancer.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24281212.001).
  • [ISSN] 2072-6694
  • [Journal-full-title] Cancers
  • [ISO-abbreviation] Cancers (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3840456
  •  go-up   go-down


52. Mogensen M, Jemec GB: Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies. Dermatol Surg; 2007 Oct;33(10):1158-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies.
  • BACKGROUND: Nonmelanoma skin cancer (NMSC) is the most prevalent cancer in the light-skinned population.
  • OBJECTIVE: The scope of this review is to present data on the current state-of-the-art diagnostic methods for keratinocyte carcinoma: basal cell carcinoma, squamous cell carcinoma, and actinic keratosis.
  • [MeSH-major] Skin Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / ultrasonography. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / ultrasonography. Dermoscopy. Diagnostic Tests, Routine. Humans. Keratosis / diagnosis. Keratosis / pathology. Keratosis / ultrasonography

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903149.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 128
  •  go-up   go-down


53. Mancuso M, Gallo D, Saran A: Re: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis; 2009 Apr;30(4):721
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Disease Models, Animal. Estrogens / pharmacology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Carcinogenesis. 2009 Apr;30(4):720 [19168587.001]
  • (PMID = 19168582.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens
  •  go-up   go-down


54. Leiter U, Garbe C: [Skin cancer in organ transplant patients. Epidemiology and management]. Hautarzt; 2010 Mar;61(3):207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin cancer in organ transplant patients. Epidemiology and management].
  • Skin cancer is the most common cancer, representing 40-50% of post transplant malignancies.
  • In the first 10 years post transplantation, some 15%-40% of patients develop skin cancer, primarily squamous cell carcinoma and basal cell carcinoma, but also melanoma, Merkel cell carcinoma and virally-induced Kaposi sarcoma.
  • The management of skin cancer includes secondary prophylaxis and address attention to areas of widespread actinic damage, usually with topical agents.
  • In high risk skin cancer or metastatic disease a substantial reduction in immunosuppression to switching to mTOR inhibitors appears to substantially improve the prognosis.
  • The management of the individual tumor types is discussed; in general it follows the current guidelines.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Immunosuppressive Agents / administration & dosage. Organ Transplantation / statistics & numerical data. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Skin Neoplasms / epidemiology. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2008 Apr;18(2):152-60 [18337653.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S15-6 [18801136.001]
  • [Cites] Am J Transplant. 2008 Sep;8(9):1891-900 [18786232.001]
  • [Cites] Curr Opin Oncol. 2009 May;21(3):232-7 [19370807.001]
  • [Cites] Transplantation. 1999 Dec 15;68(11):1717-21 [10609948.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307 [10642700.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S2-4 [18801139.001]
  • [Cites] ScientificWorldJournal. 2008 Sep 21;8:909-19 [18836658.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:40-2 [17488405.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5):783-90 [16243126.001]
  • [Cites] Am J Transplant. 2006 Sep;6(9):2164-8 [16780549.001]
  • [Cites] Transplantation. 2009 Aug 27;88(4):597-8 [19696647.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):1-12 [17520670.001]
  • [Cites] Dermatol Surg. 2009 Oct;35(10):1567-72 [19681993.001]
  • [Cites] Am J Transplant. 2008 Nov;8(11):2192-8 [18782290.001]
  • [Cites] Dermatol Surg. 2002 Feb;28(2):113-7; discussion 117 [11860419.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] Transplantation. 2006 Dec 27;82(12):1792-3 [17198278.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):35-48 [18593385.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Am J Transplant. 2004 Jun;4(6):905-13 [15147424.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S19-24 [18801138.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S9-S14 [18801142.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S5-8 [18801141.001]
  • [Cites] Transplantation. 1990 Mar;49(3):506-9 [2316011.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Sep;5(9):510-1 [18679393.001]
  • [Cites] J Am Acad Dermatol. 2008 Sep;59(3):405-17 [18556089.001]
  • [Cites] Transplant Proc. 1988 Jun;20(3 Suppl 3):885-92 [3388524.001]
  • [Cites] Melanoma Res. 2008 Feb;18(1):61-7 [18227710.001]
  • [Cites] Swiss Med Wkly. 2009 Jul 25;139(29-30):407-15 [19680830.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Transplantation. 1997 Sep 15;64(5):669-73 [9311700.001]
  • [Cites] J Clin Microbiol. 2001 Feb;39(2):506-8 [11158097.001]
  • [Cites] Br J Dermatol. 2006 Aug;155(2):451-4 [16882188.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Transplantation. 2004 Feb 27;77(4):574-9 [15084938.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:25-31 [18067628.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7 [15061846.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Jun;19(5):365-6 [17379490.001]
  • [Cites] Br J Dermatol. 2007 Dec;157(6):1183-8 [17916206.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):459-63 [11295926.001]
  • (PMID = 20145902.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


55. Kummoona R: Periorbital and orbital malignancies: methods of management and reconstruction in Iraq. J Craniofac Surg; 2007 Nov;18(6):1370-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types were squamous cell carcinoma, basal cell carcinoma, conjunctival squamous cell carcinoma, retinoblastoma, fibrosarcoma, and ectopic mixed tumor in two, one, two, one, one, and one patients, respectively, in addition to eight patients with jaw lymphoma involving the orbit, out of 24 patients reported by us.
  • Surgery consisted of complete excision of orbital content (exenteration) with or without partial orbitectomy in four patients and wide excision of the tumor in four patients.
  • Reconstruction of the defect was accomplished using various local skin flaps and temporalis muscle flap was used for augmenting the orbit in the four exenterated patients.
  • There is no single best method for reconstruction of the periorbital and orbital defects left after tumor resection, and different flaps applied for reconstruction had given satisfactory results related to the type and complexity of the deformity.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Eye Enucleation. Female. Humans. Infant. Iraq. Lymphoma / chemistry. Lymphoma / surgery. Male. Middle Aged. Radiotherapy, Adjuvant. Skin Transplantation

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993883.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Rodríguez-Domínguez FJ, Hernández-Gil J, Segarra Fenoll JD, Hernández-Gil A: [Facial mutilant basosquamous carcinoma]. An Otorrinolaringol Ibero Am; 2007;34(6):549-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Facial mutilant basosquamous carcinoma].
  • [Transliterated title] Carcinoma basoescamoso mutilante en región facial.
  • Basosquamous carcinoma is a rare epithelial malignant neoplasm with clinical and biological features of both basal and squamous cell carcinoma.
  • This neoplasm has been characterized for years as a variant of basal cell carcinoma, although now it is widely accepted as a clinical entity.
  • The most important features of basosquamous carcinoma are its great local aggressiveness, high frequency of recurrences and its metastatic potential.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Head and Neck Neoplasms / pathology. Palliative Care / methods
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Face. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293774.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


57. Tichý M, Ditrichová D, Brychtová S, Tichá V, Urbánek J: Double skin tumors with an atypical clinical picture. Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun;16(2):63-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double skin tumors with an atypical clinical picture.
  • The authors present a rare case of double skin tumors: acral lentiginous melanoma and metatypical carcinoma.
  • The skin biopsies showed advanced acral lentiginous melanoma on the sole and metatypical carcinoma of the lower leg.
  • Soon after the diagnosis was made, the melanoma generalized.
  • The article discusses the differential diagnosis of both leg ulcerations, correct diagnostic procedures, and characteristic features of both tumors that are important questions for general practitioners, dermatologists, and surgeons.
  • [MeSH-major] Carcinoma / diagnosis. Leg Ulcer / etiology. Melanoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Foot Ulcer / etiology. Humans. Male

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992460.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  •  go-up   go-down


58. Kolm I, Hofbauer G, Braun RP: [Early diagnosis of skin cancer]. Ther Umsch; 2010 Sep;67(9):439-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early diagnosis of skin cancer].
  • The skin is the most affected organ by cancer.
  • The incidence rates of skin cancer are steadily increasing, both for melanoma and non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma).
  • Over 90 % of the death cases from skin cancers attribute to melanoma.
  • In the last years a number of new non invasive techniques for the early diagnosis of melanoma have been developed which are superior to the naked eye examination.
  • In this overview article we present some non-invasive diagnostic techniques like total body photography, digital dermoscopy and confocal microscopy which in addition to dermoscopy assist the dermatologist in differentiating nevi from early melanomas.Non-melanoma skin cancer can be prevented by accurate sun protection.
  • Early squamous cell carcinomas and basal cell carcinomas can be treated either invasively or non-invasively with excellent prognosis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / prevention & control. Melanoma / diagnosis. Melanoma / prevention & control. Precancerous Conditions / diagnosis. Precancerous Conditions / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / prevention & control
  • [MeSH-minor] Dermoscopy. Early Diagnosis. Humans. Microscopy, Confocal. Photography. Risk Factors. Skin / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20806172.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


59. Dixon A, Rosengren H, Connelly T, Dixon J: Education in skin cancer management--assessing knowledge and safety. Aust Fam Physician; 2009 Jul;38(7):557-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Education in skin cancer management--assessing knowledge and safety.
  • BACKGROUND: General practitioners manage the majority of skin cancers in Australia.
  • There are a range of training opportunities for, and certifications in, skin cancer management.
  • METHOD: Between 15 June and 25 June 2008, an online examination was placed on the Australasian College of Skin Cancer Medicine website.
  • Thirty questions were asked pertaining to the management of a hypothetical case study including melanoma, basal cell carcinoma and squamous cell carcinoma.
  • Two days of training may not make doctors sufficiently safe in skin cancer management; it appeared to improved knowledge, but not to a point where unsafe practice was eliminated.
  • [MeSH-major] Family Practice / education. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575076.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


60. Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M: Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol; 2008 Feb;21(2):178-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: an immunohistochemical reappraisal.
  • Even though immunohistochemical comparisons of microcystic adnexal carcinoma vs infiltrative basal cell carcinoma and desmoplastic trichoepithelioma exist, they are mostly restricted to the use of a single stain.
  • In addition, a comparison with squamous cell carcinoma has not been reported previously.
  • In this study, we compare the expression of cytokeratin (CK) 15, CK7, CK20, CK903, carcinoembryonic antigen (CEA), CD10, CD15 and BerEP4 in 13 microcystic adnexal carcinoma, eight desmoplastic trichoepithelioma, 10 infiltrative basal cell carcinoma, and eight squamous cell carcinoma of which five exhibited ductal differentiation.
  • We found that the majority of microcystic adnexal carcinoma (92%) and desmoplastic trichoepithelioma (100%) cases expressed CK15 while the infiltrative basal cell carcinoma and squamous cell carcinoma cases were all negative.
  • Forty percent of infiltrative basal cell carcinoma expressed CK7; while only two microcystic adnexal carcinoma cases (15%) and one squamous cell carcinoma with ductal differentiation (12%) expressed CK7 in the remaining three tumor categories.
  • While the neoplastic cells were negative, luminal staining of ductal structures was noted for CK7, CD15 and CEA in some of the microcystic adnexal carcinoma, desmoplastic trichoepithelioma and squamous cell carcinoma with ductal differentiation cases.
  • Sixty percent of infiltrative basal cell carcinoma, 31% of microcystic adnexal carcinoma, and 25% of squamous cell carcinoma express CD10.
  • BerEP4 expression was noted in 38% of microcystic adnexal carcinoma, 57% of desmoplastic trichoepithelioma, 100% of infiltrative basal cell carcinoma, and 38% of squamous cell carcinoma.
  • In conclusion, we found CK15 to be a useful marker in distinguishing microcystic adnexal carcinoma from infiltrative basal cell carcinoma and squamous cell carcinoma with ductal differentiation.
  • Our experience indicates that microcystic adnexal carcinoma and desmoplastic trichoepithelioma have a similar immunohistochemical profile that is, CK15+ and BerEP4+/-; thus, additional studies are needed to separate these two entities.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Skin Appendage / chemistry. Head and Neck Neoplasms / chemistry. Immunohistochemistry / methods. Skin Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / chemistry. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / diagnosis. Diagnosis, Differential. Female. Humans. Keratin-15 / analysis. Male. Middle Aged


61. Skroza N, Panetta C, Schwartz RA, Balzani A, Rota C, Buccheri EM, Alfano C, Innocenzi D: Giant meta-typical carcinoma: an unusual tumor. Acta Dermatovenerol Croat; 2006;14(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant meta-typical carcinoma: an unusual tumor.
  • Meta-typical carcinoma (MTC) or basosquamous carcinoma is a remarkable malignancy with features of both basal and squamous cell carcinoma.
  • It is typically located on the back and face, often with clinical features of basal cell carcinoma but tending to be more aggressive with enhanced prospects of lymph node or distant metastases.
  • Our report describes a huge neglected MTC of the back of ten-year duration, a giant ulcero-vegetative tumor measuring 20 x 25 cm.
  • Histologic examination of specimens from the margins and periphery revealed aspects of both basal and squamous cell carcinoma, while the ulcerated center showed sclerotic tissue without tumor.
  • This may have been related to an intense inflammatory host response with elimination of neoplastic tissue and consequent local sclerosis evident in the central tumor-free portion.
  • This central tumor regression is to our knowledge a unique finding in MTC.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603102.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


62. Hönigsmann H, Diepgen TL: [UV-induced skin cancers]. J Dtsch Dermatol Ges; 2005 Sep;3 Suppl 2:S26-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [UV-induced skin cancers].
  • In this review the epidemiology and pathogenetic aspects of UV-induced malignant skin tumours (basal cell carcinoma, squamous cell carcinoma and melanoma) are discussed with regard to current literature.
  • Whereas present knowledge, in particular, gained from experimental data, permits substantial conclusions about the development of squamous cell carcinoma, the situation for basal cell carcinoma and melanoma does not appear to be unequivocally clear.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Melanoma / etiology. Neoplasms, Radiation-Induced / etiology. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Adolescent. Age Factors. Child. DNA Damage. DNA Repair. Humans. Risk Factors. Skin / pathology. Sunburn / complications

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16117740.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 37
  •  go-up   go-down


63. McKnight CA, Wise AG, Maes RK, Howe C, Rector A, Van Ranst M, Kiupel M: Papillomavirus-associated basosquamous carcinoma in an Egyptian fruit bat (Rousettus aegyptiacus). J Zoo Wildl Med; 2006 Jun;37(2):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillomavirus-associated basosquamous carcinoma in an Egyptian fruit bat (Rousettus aegyptiacus).
  • Six additional variably sized, raised, smooth to cauliflower-like skin masses were observed randomly distributed throughout the left wing membranes.
  • Four masses were removed and diagnosed microscopically as basosquamous carcinomas and papillomas.
  • Additional masses, removed 6 mo and 1 yr later, showed bony invasion and squamous differentiation.
  • Polymerase chain reaction done on DNA extracts from formalin-fixed, paraffin-embedded tumor tissue amplified a 450 base-pair segment analogous to the L1 region of human papillomavirus types 96 and 5.
  • To our knowledge, this is the first report of papillomavirus-associated carcinoma in a chiropteran species.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Chiroptera / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312801.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Tarallo M, Cigna E, Frati R, Delfino S, Innocenzi D, Fama U, Corbianco A, Scuderi N: Metatypical basal cell carcinoma: a clinical review. J Exp Clin Cancer Res; 2008;27:65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metatypical basal cell carcinoma: a clinical review.
  • BACKGROUND: Metatypical cell carcinoma can be considered as a new entity of skin cancer, being an intermediate typology between basal cell carcinomas and squamous cell carcinomas.
  • The behaviour of the metatypical cell carcinoma lies between these two varieties of skin cancer.
  • It is difficult to perform a differential diagnosis based on morphological and clinical features - therefore it is only possible by accurate histology.
  • METHODS: The authors have retrospectively analysed clinical records of 240 patients who were affected by metatypical skin cancer and who were treated by surgery, radiotherapy and chemotherapy.
  • CONCLUSION: In this manuscript, the authors have emphasised the importance of conducting a differential diagnosis, and the importance of the specific treatment for metatypical skin cancer, even though more clinical studies and long-term follow-ups are required before establishing specific guidelines.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):224-30 [11174379.001]
  • [Cites] Plast Reconstr Surg. 2001 Apr 1;107(4):942-7 [11252086.001]
  • [Cites] Plast Reconstr Surg. 2002 Apr 1;109(4):1466-7 [11965016.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):551-8 [12461611.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 May;128(5):663-73 [12748559.001]
  • [Cites] Dermatol Surg. 2003 Jul;29(7):700-11 [12828693.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):830-2; discussion 833 [12859383.001]
  • [Cites] J Craniomaxillofac Surg. 2004 Feb;32(1):16-8 [14729044.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):248-52 [14871217.001]
  • [Cites] Br J Ophthalmol. 2004 Mar;88(3):358-60 [14977769.001]
  • [Cites] Acta Derm Venereol. 2004;84(1):44-7 [15040477.001]
  • [Cites] Arch Facial Plast Surg. 2004 May-Jun;6(3):158-61 [15148122.001]
  • [Cites] Br J Oral Maxillofac Surg. 2004 Aug;42(4):311-4 [15225948.001]
  • [Cites] Arch Dermatol. 1965 Dec;92(6):635-7 [5846318.001]
  • [Cites] Br J Dermatol. 1973 Jul;89(1):37-43 [4788317.001]
  • [Cites] Ophthalmologica. 1983;187(1):51-8 [6877760.001]
  • [Cites] Arkh Patol. 1983;45(6):35-9 [6625927.001]
  • [Cites] J Am Acad Dermatol. 1984 Oct;11(4 Pt 1):557-62 [6490979.001]
  • [Cites] Dermatologica. 1985;171(1):21-6 [2411609.001]
  • [Cites] Arch Dermatol. 1987 Mar;123(3):340-4 [3813602.001]
  • [Cites] J Dermatol Surg Oncol. 1987 May;13(5):556-7 [3571694.001]
  • [Cites] J Dermatol Surg Oncol. 1988 Jun;14(6):600-2 [3372843.001]
  • [Cites] Dermatol Clin. 1988 Jul;6(3):397-405 [3048822.001]
  • [Cites] Mod Pathol. 1991 May;4(3):325-30 [2068058.001]
  • [Cites] J Am Acad Dermatol. 1992 Jan;26(1):1-26 [1732313.001]
  • [Cites] Pathol Res Pract. 1991 Dec;187(8):978-85 [1792194.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8 [1430364.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):6S-9S [8006441.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):667-73 [7804993.001]
  • [Cites] Arkh Patol. 1994 Jul-Aug;56(4):35-8 [7848103.001]
  • [Cites] Ann Chir Plast Esthet. 1994 Apr;39(2):176-83 [7872634.001]
  • [Cites] Am J Surg. 1995 Nov;170(5):446-50 [7485729.001]
  • [Cites] Laryngoscope. 1996 Feb;106(2 Pt 1):156-8 [8583845.001]
  • [Cites] Am J Dermatopathol. 1996 Feb;18(1):35-42 [8721589.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):279-81; discussion 281-2 [9218319.001]
  • [Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):430-7 [9308559.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):627-36 [9342506.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):673-86 [9342510.001]
  • [Cites] J Cutan Pathol. 1998 Mar;25(3):153-9 [9550314.001]
  • [Cites] Br J Plast Surg. 1999 Jan;52(1):24-8 [10343586.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Semin Cutan Med Surg. 2004 Sep;23(3):167-73 [15584682.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):170-5 [15929123.001]
  • [Cites] Br J Plast Surg. 2005 Sep;58(6):795-805 [16086990.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):464-8 [16112354.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2007;60(1):41-7 [17126265.001]
  • [Cites] Eur J Dermatol. 2000 Jun;10(4):315-6 [10939863.001]
  • [Cites] Br J Oral Maxillofac Surg. 2000 Oct;38(5):477-9 [11010777.001]
  • [Cites] J Natl Compr Canc Netw. 2004 Jan;2(1):2 [19777690.001]
  • (PMID = 18992138.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 55
  • [Other-IDs] NLM/ PMC2585560
  •  go-up   go-down


65. Schouten HW, Knippels MC, Franken RJ: [Maggots in the wound, debridement, disinfection and wound healing]. Ned Tijdschr Geneeskd; 2009;153:A624
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Vliegenmaden in de wond: débridement, desinfectie en wondgenezing.
  • An 87-year-old man had a longstanding untreated large basosquamous carcinoma on his right ear.
  • A striking finding was that the smell of the wound had disappeared and that the wound was much cleaner, with a reddish aspect and less necrosis.
  • [MeSH-minor] Aged, 80 and over. Animals. Carcinoma, Basosquamous / complications. Carcinoma, Basosquamous / parasitology. Carcinoma, Basosquamous / surgery. Ear Neoplasms / complications. Ear Neoplasms / parasitology. Ear Neoplasms / surgery. Humans. Larva. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900320.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


66. Akyol M, Ozçelik S: Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol; 2005;6(3):175-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diseases such as psoriasis, pityriasis rubra pilaris, condylomata acuminata, skin cancers, rosacea, hidradenitis suppurativa, granuloma annulare, lupus erythematosus and lichen planus have been shown to respond to the immunomodulatory, anti-inflammatory and antitumor activities of the drug.
  • Isotretinoin also helps prevent skin cancers such as basal cell carcinoma or squamous cell carcinoma.
  • A combination of systemic isotretinoin and interferon-alpha-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment of skin cancers.Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Dermatologic Agents / therapeutic use. Isotretinoin / therapeutic use. Skin Diseases / drug therapy
  • [MeSH-minor] Acne Vulgaris / drug therapy. Anti-Bacterial Agents / therapeutic use. Condylomata Acuminata / drug therapy. Drug Therapy, Combination. Granuloma Annulare / drug therapy. Hidradenitis Suppurativa / drug therapy. Humans. Keratolytic Agents / therapeutic use. Lichen Planus / drug therapy. Lupus Erythematosus, Systemic / drug therapy. Pityriasis Rubra Pilaris / drug therapy. Psoriasis / drug therapy. Rosacea / drug therapy. Sebaceous Glands / drug effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943494.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents; 0 / Keratolytic Agents; EH28UP18IF / Isotretinoin
  • [Number-of-references] 133
  •  go-up   go-down


67. Ishihara K, Saida T, Otsuka F, Yamazaki N, Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society: Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol; 2008 Feb;13(1):33-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
  • BACKGROUND: In the previous report of the Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, we tabulated data on patients with malignant melanoma who had been registered at major medical institutions (22 institutions on average) in Japan over 5-year periods from 1987 to 1991 (group A) and from 1992 to 1996 (group B).
  • In the present study, patients registered from 1997 to 2001 (group C) were investigated and the data were compared with findings obtained by the subsequent follow-up of groups A and B.
  • Because the International Union Against Cancer (UICC) TNM and stage classifications for malignant melanoma were changed substantially in 2002, analyses in the present investigation were performed according to the new classifications.
  • In addition, the numbers of patients with various kinds of skin malignancies, including not only malignant melanoma but also basal cell carcinoma, squamous cell carcinoma, mycosis fungoides, actinic keratosis, Bowen's disease, and Paget's disease, registered at approximately 100 medical institutions in Japan from 1987 to 2001, were also investigated and data were tabulated.
  • RESULTS: The nationwide survey of Japanese patients with malignant skin tumors from 1987 to 2001 showed that the most prevalent skin tumor was basal cell carcinoma, which increased year by year, followed by squamous cell carcinoma, and then by malignant melanoma.
  • The following results were obtained from the data for melanoma patients registered at major institutions from 1987 to 2001. (1) The overall 10-year survival rates for melanoma patients in each chronological group were ranked as: group C > B > A, although only the difference between groups C and A was statistically significant. (2) The male-to-female ratio ranged from 1: 0.97 to 1: 1.14, and the survival rate of female patients was higher than that of male patients (the 140-month survival rate was 70.6% in females and 60% in males). (3) Assessment of the age distribution showed that the number of patients increased rapidly from ages 40-49 years and reached a peak at around 60 years in all three groups. (4) The sole of the foot was the most common site of melanoma in both males and females, while melanomas on the lower limbs were also prevalent in females. (5) Acral lentiginous melanoma (ALM) was the most common type in all three groups, accounting for nearly 50% of the patients in each group.
  • The prognosis of NM was the worst, while that of SSM was the most favorable. (6) The proportion of stage I patients was larger in group C than in groups A and B, but no significant difference among the groups was observed in the proportions of stage II, III, and IV patients.
  • For patients in stage IV, the survival rate in group C was slightly lower than that in group A or B. (7) In group C, the overall survival rates for substages III A, B, and C were ranked as III A > III B > III C. (8) The overall survival rates for stage IV M1a, M1b, and M1c were ranked as M1a > M1b > M1c.
  • CONCLUSION: In Japan, the number of patients with malignant skin tumors has increased year by year.
  • The prognosis of patients with advanced malignant melanoma remains extremely poor, but that of patients in stage III has shown an improvement.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 1995 Oct;24(5):897-907 [8557445.001]
  • [Cites] Int J Clin Oncol. 2003 Jun;8(3):139-50 [12851837.001]
  • [Cites] Int J Clin Oncol. 2001 Jun;6(3):109-16 [11706778.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1484-91 [10717634.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Harefuah. 1995 Jun 15;128(12):745-51, 824 [7557679.001]
  • (PMID = 18307017.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


68. Malejczyk M, Józwiak J, Jablonska S, Pfister H, Majewski S, Malejczyk J: Circulating soluble tumour necrosis factor receptors in patients with epidermodysplasia verruciformis as compared to patients with cutaneous tumours in the general population. Oncol Rep; 2005 Jan;13(1):151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soluble tumour necrosis factor receptors type I and II (sTNF-RI and II) were evaluated in sera from patients with epidermodysplasia verruciformis and patients with cutaneous warts, actinic keratoses, squamous cell carcinomas or basal cell carcinomas by specific enzyme-linked immunobiological assays.
  • The levels of sTNF-RI were significantly increased in patients with multiple actinic keratoses, squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Epidermodysplasia Verruciformis / diagnosis. Receptors, Tumor Necrosis Factor, Type I / blood. Receptors, Tumor Necrosis Factor, Type II / blood
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Skin Neoplasms / diagnosis. Skin Neoplasms / metabolism

  • Genetic Alliance. consumer health - Epidermodysplasia Verruciformis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583817.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II
  •  go-up   go-down


69. Sengupta SR, Das NK, Datta PK: Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol; 2008 Nov-Dec;74(6):559-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenicosis is a multisystem disorder, with virtually no system spared from its vicious claw; though its predominant manifestations are linked to cutaneous involvement.
  • Cutaneous effects take the form of pigmentary changes, hyperkeratosis, and skin cancers (Bowen's disease, squamous cell carcinoma, and basal cell epithelioma).
  • Peripheral vascular disease (blackfoot disease), hypertension, ischemic heart disease, noncirrhotic portal hypertension, hepatomegaly, peripheral neuropathy, respiratory and renal involvement, bad obstetrical outcome, hematological disturbances, and diabetes mellitus are among the other clinical features linked to arsenic toxicity.
  • Understandably the detoxification/bio-inactivation process is not a complete defense against the vicious metalloid, and it can cause chromosomal aberration, impairment of DNA repair process, alteration in the activity of tumor suppressor gene, etc., leading to genotoxicity and carcinogenicity.
  • Increased expression of cytokeratins, keratin-16 (marker for hyperproliferation) and keratin-8 and -18 (marker for less differentiated epithelial cells), can be related to the histopathological findings of hyperkeratosis and dysplastic cells in the arsenicosis skin lesion.
  • [MeSH-major] Arsenic Poisoning / epidemiology. Arsenic Poisoning / pathology. Skin Diseases / epidemiology. Skin Diseases / pathology
  • [MeSH-minor] Animals. Arsenic / adverse effects. Chronic Disease. Environmental Exposure / adverse effects. Humans. Water Pollutants / adverse effects. World Health Organization

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171978.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Water Pollutants; N712M78A8G / Arsenic
  • [Number-of-references] 115
  •  go-up   go-down


70. Rollison DE, Pawlita M, Giuliano AR, Iannacone MR, Sondak VK, Messina JL, Cruse CW, Fenske NA, Glass LF, Kienstra M, Michael KM, Waterboer T, Gheit T, Tommasino M: Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. Int J Cancer; 2008 Nov 15;123(10):2337-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers.
  • Cutaneous human papillomavirus (HPV) may be associated with the development of nonmelanoma skin cancer (NMSC), as suggested by reports of HPV DNA in NMSC tumors.
  • NMSC tumor tissue was obtained from 20 patients with pathology-confirmed basal or squamous cell carcinoma of the skin, in addition to several normal tissues, including eyebrow hairs, normal skin swabs obtained using multiple techniques, normal skin punch and shave biopsies, and serum for antibody measurement.
  • Using HPV DNA in tumor tissues as a gold standard, sensitivity and specificity were calculated for each measure of HPV infection in normal tissues. beta-Papillomavirus DNA was observed in tumor tissues in 60% of patients.
  • The normal skin punch biopsy demonstrated optimal sensitivity (75%) and specificity (75%).
  • [MeSH-major] Biomarkers / metabolism. Papillomavirus Infections / virology. Skin Diseases, Viral / virology. Skin Neoplasms / virology
  • [MeSH-minor] Betapapillomavirus / isolation & purification. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / virology. Enzyme-Linked Immunosorbent Assay. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18729188.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


71. Heneghan MK, Hazan C, Halpern AC, Oliveria SA: Skin cancer coverage in a national newspaper: a teachable moment. J Cancer Educ; 2007;22(2):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer coverage in a national newspaper: a teachable moment.
  • BACKGROUND: The objectives of this study were to (1) identify the number of published articles related to skin cancer in The New York Times newspaper from 1980-2004;.
  • (2) assess the content of the articles related to skin cancer, and (3) examine the trends in media coverage of skin cancer over time.
  • METHODS: We performed a content analysis on articles related to skin cancer appearing in The New York Times during January 1, 1980, through December 31, 2004, using the ProQuest online content repository database and key words skin cancer.
  • We conducted an advanced focus search of all "skin cancer" articles using key words "melanoma," "squamous cell carcinoma," "basal cell carcinoma," "sunscreen," "tanning," "sunbathing," and "tanning salon".
  • RESULTS: We identified 874 published articles relating to skin cancer.
  • Coverage of other major subjects included sunscreen (11%), tanning (9%), basal cell carcinoma (7%), squamous cell carcinoma (3%), sunbathing (2%), and tanning salon (2%).
  • The remaining 37% of articles contained some mention of skin cancer, but skin cancer was not the main topic nor were any of the focus terms.
  • Over the 25-year period we examined, there was a slight upward trend in the number of skin-cancer-related articles, although we observed year-to-year variation.
  • CONCLUSIONS: Understanding how the print media portrays skin cancer issues provides valuable feedback for federal agencies and cancer organizations and may ultimately help promote skin cancer prevention and education.
  • [MeSH-major] Bibliometrics. Health Education. Journalism, Medical. Newspapers as Topic. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Health Commun. 2000 Apr-Jun;5(2):117-34 [11010345.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jul;62(1):71-9 [10989987.001]
  • [Cites] Am J Public Health. 1989 Nov;79(11):1551-2 [2683815.001]
  • [Cites] AIDS Educ Prev. 1992 Winter;4(4):295-307 [1472415.001]
  • [Cites] Adolescence. 1996 Summer;31(122):253-64 [8726887.001]
  • [Cites] J Am Acad Dermatol. 1986 Apr;14(4):676-9 [3958278.001]
  • [Cites] J Commun. 1975 Summer;25(3):171-3 [1184780.001]
  • [Cites] J Am Acad Dermatol. 1997 Aug;37(2 Pt 1):179-86 [9270501.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):491-6 [15837868.001]
  • [Cites] Addiction. 1997 Jun;92 Suppl 2:S189-99 [9231444.001]
  • [Cites] Prev Med. 2005 Aug;41(2):511-20 [15917047.001]
  • [Cites] Clin Exp Dermatol. 1993 Sep;18(5):396-400 [8252756.001]
  • [Cites] Am J Prev Med. 2004 Jul;27(1):57-65 [15212776.001]
  • [Cites] Health Educ Q. 1996 Aug;23(3):346-64 [8841819.001]
  • [Cites] Public Health Rep. 1982 Mar-Apr;97(2):113-5 [7063590.001]
  • [Cites] J Womens Health Gend Based Med. 2000 Jun;9(5):471-5 [10883937.001]
  • [Cites] J Am Acad Dermatol. 1996 Jun;34(6):971-8 [8647990.001]
  • [Cites] Prev Med. 1992 Sep;21(5):654-69 [1438112.001]
  • [Cites] Arch Intern Med. 1989 Jan;149(1):140-4 [2912403.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1180-3 [1891034.001]
  • [Cites] J Am Diet Assoc. 1977 Nov;71(5):505-9 [615901.001]
  • [Cites] Am J Public Health. 1992 Oct;82(10):1374-6 [1415863.001]
  • [Cites] J Community Health. 1992 Jun;17(3):153-65 [1512306.001]
  • [Cites] J Clin Epidemiol. 1993 Sep;46(9):987-1001 [8263584.001]
  • [Cites] Eval Rev. 1996 Aug;20(4):404-23 [10183257.001]
  • [Cites] Arch Intern Med. 2003 Jul 14;163(13):1601-5 [12860585.001]
  • [Cites] Lancet. 1996 Jun 8;347(9015):1600-3 [8667872.001]
  • [Cites] J Pediatr Psychol. 1994 Feb;19(1):3-17; discussion 19-26 [8151494.001]
  • [Cites] Tob Control. 2003 Sep;12 Suppl 2:ii75-81 [12878777.001]
  • [Cites] J Am Acad Dermatol. 1999 Jul;41(1):81-99 [10411417.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] N Engl J Med. 1998 Jul 9;339(2):87-92 [9654540.001]
  • [Cites] JAMA. 1998 Mar 11;279(10):762-6 [9508152.001]
  • (PMID = 17605623.001).
  • [ISSN] 0885-8195
  • [Journal-full-title] Journal of cancer education : the official journal of the American Association for Cancer Education
  • [ISO-abbreviation] J Cancer Educ
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K07 CA94002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


72. Kimball KJ, Straughn JM, Conner MG, Kirby TO: Recurrent basosquamous cell carcinoma of the vulva. Gynecol Oncol; 2006 Aug;102(2):400-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basosquamous cell carcinoma of the vulva.
  • BACKGROUND: Basosquamous cell carcinoma (BSC) of the vulva is a rare entity with interesting prognostic and therapeutic implications.
  • CONCLUSION: BSC is a rare disorder of the vulva.
  • The metastatic potential of this tumor is not fully understood, but likely is intermediate between squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Basosquamous / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624392.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Snarskaia ES, Molochkov VA, Frank GA, Zavalishina LA: [Matrix metalloproteinases and their tissue inhibitors in basal cell and metatypical cancer of the skin]. Arkh Patol; 2005 May-Jun;67(3):14-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Matrix metalloproteinases and their tissue inhibitors in basal cell and metatypical cancer of the skin].
  • 10 cases of ulcerative-nodular basal cell carcinoma and 10 cases of metatypical carcinoma of the skin were studied immunohistochemically for immunoexpression of matrix metalloproteinases (MMP-1, MMP-9) and their endogenic tissue inhibitors (TIMP-1, TIMP-2) in combination with PCNA, p53 tumor complexes.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Matrix Metalloproteinase 1 / analysis. Matrix Metalloproteinase 9 / analysis. Skin Neoplasms / diagnosis. Tissue Inhibitor of Metalloproteinases / analysis
  • [MeSH-minor] Diagnosis, Differential. Humans. Proliferating Cell Nuclear Antigen / analysis. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16075605.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tissue Inhibitor of Metalloproteinases; 0 / Tumor Suppressor Protein p53; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


74. Rector A, Mostmans S, Van Doorslaer K, McKnight CA, Maes RK, Wise AG, Kiupel M, Van Ranst M: Genetic characterization of the first chiropteran papillomavirus, isolated from a basosquamous carcinoma in an Egyptian fruit bat: the Rousettus aegyptiacus papillomavirus type 1. Vet Microbiol; 2006 Oct 31;117(2-4):267-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic characterization of the first chiropteran papillomavirus, isolated from a basosquamous carcinoma in an Egyptian fruit bat: the Rousettus aegyptiacus papillomavirus type 1.
  • The complete genomic DNA of a novel papillomavirus (PV) was isolated from a basosquamous carcinoma on the wing of an Egyptian fruit bat (Rousettus aegyptiacus).
  • Since RaPV-1 is only distantly related to other papillomaviruses (with maximally 50% nucleotide sequence identity across the L1 open reading frame), it cannot be assigned to one of the existing papillomavirus genera and therefore represents the first member of a novel, as yet unnamed, close-to-root papillomavirus genus.
  • [MeSH-major] Carcinoma, Basosquamous / veterinary. Chiroptera / virology. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854536.001).
  • [ISSN] 0378-1135
  • [Journal-full-title] Veterinary microbiology
  • [ISO-abbreviation] Vet. Microbiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Transposable Elements; 0 / DNA, Viral
  •  go-up   go-down


75. Ostler DA, Prieto VG, Reed JA, Deavers MT, Lazar AJ, Ivan D: Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases. Mod Pathol; 2010 Apr;23(4):567-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases.
  • This study examines adipophilin expression in various sebaceous lesions and other cutaneous tumors with a clear cell histology that may mimic sebaceous differentiation.
  • A total of 117 cutaneous clear cell lesions including 16 sebaceous adenomas, 25 sebaceous carcinomas, 8 basal cell carcinomas, 12 squamous cell carcinomas, 6 xanthomas, 10 xanthelasmas, 10 xanthogranulomas, 4 balloon cell nevi, 5 trichilemmomas, 8 clear cell hidradenomas, and 13 metastatic renal cell carcinomas were examined using immunohistochemistry for the expression of adipophilin.
  • Adipophilin was expressed in 16 of 16 (100%) sebaceous adenomas, 23 of 25 (92%) sebaceous carcinomas, 10 of 10 (100%) xanthelasmas, 9 of 10 (90%) xanthogranulomas, 6 of 6 (100%) xanthomas, and 9 of 13 (62.5%) metastatic renal cell carcinomas.
  • Adipophilin expression was not seen in any of the other lesions with clear cell histology, basal cell carcinomas, or squamous cell carcinomas, including cases that had focal clear cell differentiation.
  • Adipophilin can be valuable in an immunohistochemical panel when evaluating cutaneous lesions with clear cell histology as it identifies intracytoplasmic lipid vesicles in sebaceous and xanthomatous lesions.
  • In periocular lesions, it is effective in helping to exclude basal cell carcinoma and squamous cell carcinoma when sebaceous carcinoma is under consideration.
  • Adipophilin expression is not as useful for the differential diagnosis that includes metastatic renal cell carcinoma, a rare but important, diagnostic differential.
  • [MeSH-major] Biomarkers, Tumor / analysis. Peptides / metabolism. Sebaceous Gland Neoplasms / metabolism. Sebaceous Gland Neoplasms / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Membrane Proteins. Middle Aged. Neoplasms, Adnexal and Skin Appendage / metabolism. Neoplasms, Adnexal and Skin Appendage / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118912.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Peptides; 0 / perilipin 2
  •  go-up   go-down


76. Panda S: Nonmelanoma skin cancer in India: current scenario. Indian J Dermatol; 2010 Oct;55(4):373-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonmelanoma skin cancer in India: current scenario.
  • Incidence of skin cancers has been increasing since the last few decades worldwide.
  • Nonmelanoma skin cancer (NMSC) is the commonest variety of cutaneous malignancy.
  • Conventional wisdom has it that the incidence of all varieties of skin cancers is lower among Indians due to the protective effects of melanin.
  • Reports of quite a few atypical cases lead us to hypothesize that factors other than ultraviolet radiation may be important in the occurrences of these cancers, particularly in the skin types prevalent in India.
  • The descriptive epidemiology and clinical characteristics of squamous and basal cell carcinoma in India, including their variants, are discussed here along with hypotheses on their etiopathogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):138-50 [10863242.001]
  • [Cites] Arch Dermatol. 2000 Jun;136(6):800 [10871955.001]
  • [Cites] Australas J Dermatol. 1997 Jun;38 Suppl 1:S31-5 [10994469.001]
  • [Cites] Cancer. 1975 Mar;35(3):600-5 [1111931.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):497-9 [11209121.001]
  • [Cites] Hautarzt. 2002 Feb;53(2):118-20 [11963191.001]
  • [Cites] Am J Dermatopathol. 2002 Apr;24(2):144-8 [11979075.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • [Cites] Cancer. 1992 Jul 1;70(1):104-8 [1606530.001]
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] Ann Univ Mariae Curie Sklodowska Med. 2004;59(2):498-502 [16146137.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2005 Nov-Dec;71(6):414-6 [16394484.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2005 Nov-Dec;71(6):430-1 [16394491.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2007 Mar-Apr;73(2):127-8 [17456927.001]
  • [Cites] Arch Dermatol Res. 2008 Apr;300 Suppl 1:S43-50 [17985102.001]
  • [Cites] Int J Dermatol. 2008 Jan;47(1):59-60 [18173605.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2008 Nov-Dec;74(6):662-4 [19172004.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] Indian J Dermatol. 2008;53(3):137-9 [19882013.001]
  • [Cites] Indian J Dermatol. 2008;53(3):140-1 [19882014.001]
  • [Cites] Indian J Dermatol. 2008;53(4):192-4 [19882033.001]
  • [Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]
  • [Cites] Indian J Dermatol. 2009;54(1):46-8 [20049269.001]
  • [Cites] Indian J Dermatol. 2009;54(2):196-9 [20101326.001]
  • [Cites] Indian J Dermatol. 2009;54(4):342-6 [20101335.001]
  • [Cites] Indian J Dermatol. 2010 Oct;55(4):363-6 [21430891.001]
  • [Cites] Indian J Dermatol. 2009 Jul;54(3):247-50 [20161856.001]
  • [Cites] Indian J Dermatol. 2009 Jul;54(3):225-8 [20161851.001]
  • [Cites] Indian J Dermatol. 2010 Oct;55(4):387-9 [21430898.001]
  • [Cites] Indian J Dermatol. 2009 Jul;54(3):283-6 [20161865.001]
  • [Cites] Indian J Dermatol. 2010 Apr-Jun;55(2):178-80 [20606890.001]
  • [Cites] Indian J Dermatol. 2010 Apr-Jun;55(2):201-4 [20606900.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2010 Jul-Aug;76(4):420-2 [20657132.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21 [2212139.001]
  • [Cites] J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1118-26 [2273112.001]
  • [Cites] N Engl J Med. 1989 Dec 7;321(23):1577-83 [2511446.001]
  • [Cites] Histopathology. 1989 Feb;14(2):129-39 [2540085.001]
  • [Cites] J Am Acad Dermatol. 1988 Feb;18(2 Pt 1):292-8 [3346413.001]
  • [Cites] Arch Dermatol. 1988 Aug;124(8):1244-5 [3401029.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):118-20 [3581025.001]
  • [Cites] Cancer. 1974 Oct;34(4):1333-8 [4422100.001]
  • [Cites] Ann Surg. 1973 Jan;177(1):1-7 [4682500.001]
  • [Cites] J Surg Oncol. 1973 May;5(5):431-63 [4752463.001]
  • [Cites] Arch Dermatol. 1971 Aug;104(2):124-7 [5093166.001]
  • [Cites] J Am Acad Dermatol. 1980 Feb;2(2):155-60 [6245113.001]
  • [Cites] J Am Acad Dermatol. 1983 Oct;9(4):487-502 [6355213.001]
  • [Cites] Am J Dermatopathol. 1984 Apr;6(2):187-93 [6375422.001]
  • [Cites] Cancer Invest. 1983;1(2):119-26 [6667401.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):173-5 [6850540.001]
  • [Cites] Cancer. 1982 Jan 15;49(2):350-3 [7053833.001]
  • [Cites] Cancer. 1981 Mar 15;47(6):1436-8 [7226069.001]
  • [Cites] J Am Acad Dermatol. 1981 Nov;5(5):535-43 [7298919.001]
  • [Cites] Clin Plast Surg. 1980 Jul;7(3):301-11 [7438701.001]
  • [Cites] Arch Dermatol. 1998 Mar;134(3):333-7 [9580120.001]
  • [Cites] JAMA. 1977 Aug 8;238(6):513 [327111.001]
  • (PMID = 21430894.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3051301
  • [Keywords] NOTNLM ; Squamous cell carcinoma / basal cell carcinoma / nonmelanoma skin cancer
  •  go-up   go-down


77. Leibovitch I, Huilgol SC, Selva D, Lun K, Richards S, Paver R: Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol; 2005 Feb;52(2):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery.
  • BACKGROUND: Microcystic adnexal carcinoma (MAC) is reported to have a high rate of recurrence with standard wide local excision.
  • METHODS: This prospective, multi-center case series included all patients in Australia treated with MMS for MAC, who were monitored by the Skin and Cancer Foundation between 1993 and 2002.
  • In 31.8% of cases it was a recurrent tumor.
  • In 32.5% of cases the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Skin Appendage / surgery. Mohs Surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Australia / epidemiology. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Child. Databases, Factual. Diagnostic Errors. Female. Follow-Up Studies. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prospective Studies. Retrospective Studies. Treatment Outcome


78. Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS: Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin. J Surg Oncol; 2008 Jun 1;97(7):615-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
  • BACKGROUND: This study evaluates several tumor-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of squamous cell carcinoma and basal cell carcinoma.
  • METHODS: Ninety-four cases of squamous cell carcinoma and 108 cases of basal cell carcinoma using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
  • RESULTS: The depth of invasion showed a correlation with CD44v6 expression of tumor cell in both squamous cell carcinoma and basal cell carcinoma (P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal cell in squamous cell carcinoma (P = 0.010).
  • The differentiation of squamous cell carcinoma was correlated with Ki-67 index.
  • The loss of palisading arrangement in basal cell carcinoma was correlated with the MMP-1 expression of stromal cells (P = 0.045).
  • CONCLUSIONS: CD44v6 and MMP-1, expressed in tumor cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in squamous cell carcinoma and basal cell carcinoma of the skin and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / biosynthesis


79. Stoebner PE, Le Gallic L, Berthe ML, Boulle N, Lallemant B, Marque M, Gaspard C, Delfour C, Lavabre-Bertrand T, Martinez J, Meunier L: Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas. Exp Dermatol; 2008 Nov;17(11):908-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
  • Thymidine phosphorylase (TP)/platelet-derived endothelial cell growth factor is associated with tumor angiogenesis.
  • We evaluated the TP mRNA and protein expression in basal cell carcinomas (BCC) and in various skin tumors including numerous BCC histological simulants.
  • Immunohistochemistry was performed on 99 paraffin sections of formalin-fixed skin tumors using monoclonal antibodies (mAb) against TP.
  • TP mRNA levels were measured by real time RT-PCR in whole BCCs (wBCC) and laser capture microdissected (LCM) BCC tumor cells.
  • TP immunostaining was negative in all BCC variants and in most of the benign trichogeneic tumors studied.
  • By contrast, TP was constantly immunodetected in actinic keratosis (AK), squamous cell carcinomas (SCC), syringomatous carcinomas (SC), basosquamous carcinomas (BSC) and melanomas.
  • TP mRNA levels were low and statistically not different in wBCC and normal skin but were strongly downregulated in LCM-BCC as compared with LCM-normal epidermis.
  • We concluded that (i) anti-TP mAb is an useful marker to differentiate BCC from AK, SCC, BSC and SC but not from trichoblastic tumors, (ii) the lack of TP protein expression in BCC tumoral cells is linked to transcriptional regulatory mechanisms, (iii) the low TP mRNA levels in whole BCC may be related to the low intra-tumoral microvessel density, the slow growth and the very low metastatic potential of these tumors.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Thymidine Phosphorylase / genetics
  • [MeSH-minor] Carcinoma, Basosquamous / genetics. Carcinoma, Basosquamous / metabolism. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Keratosis, Actinic / genetics. Keratosis, Actinic / metabolism. Keratosis, Actinic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341568.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


80. Massari LP, Kastelan M, Gruber F: Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis. Coll Antropol; 2007 Jan;31 Suppl 1:83-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis.
  • Basal cell carcinoma and squamous cell carcinoma, collectively termed non-melanoma skin cancers are the most common malignant tumors in humans.
  • Basal cell carcinoma grows slowly and metastatic spread is very rare.
  • Squamous cell carcinoma is characterized by infiltrative, destructive growth and metastasis.
  • Long-term exposure of skin to UV light has a great impact on development of these epidermal malignancies.
  • The major role in development of skin cancer is given to proapoptotic p53 molecule or tumor suppressor gene which mutation due to UV exposure leads to resistance of DNA-damaged cell to apoptosis.
  • Other proapoptotic molecules such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) are strongly expressed in basal cell carcinoma and squamous cell carcinoma that could be explained by the ability of tumor to escape the attack of immune system.
  • [MeSH-major] Apoptosis. Carcinoma, Basal Cell / physiopathology. Carcinoma, Squamous Cell / physiopathology. Neoplasms, Radiation-Induced / physiopathology. Skin Neoplasms / physiopathology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17469758.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 29
  •  go-up   go-down


81. Zamanian A, Mahjub H, Mehralian A: Skin diseases in kidney transplant recipients. Urol J; 2006;3(4):230-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin diseases in kidney transplant recipients.
  • INTRODUCTION: The aim of this study was to evaluate the frequency of skin diseases in kidney transplant recipients.
  • The patients were examined by a dermatologist and diagnosis was made on the basis of clinical observations.
  • RESULTS: Of the patients, 226 (97%) suffered from one or more skin lesions.
  • Also, infectious and premalignant or malignant lesions (actinic keratosis, squamous cell carcinoma, and basal cell carcinoma) were seen in 48.9% and 14.2% of the patients.
  • The mean duration of immunosuppressive therapy was significantly higher in patients with infectious skin diseases (P < .001).
  • CONCLUSION: Skin lesions are a significant problem in kidney transplant recipients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559047.001).
  • [ISSN] 1735-1308
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


82. Tarstedt M, Larkö O, Molin L, Wennberg AM: [Increasing number of skin cancer cases--also among the younger]. Lakartidningen; 2005 Jun 27-Jul 10;102(26-27):1972-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Increasing number of skin cancer cases--also among the younger].
  • The incidence of skin cancer has been increasing for several years.
  • This is the case in malignant melanoma as well as in squamous cell carcinoma and basal cell carcinoma.
  • Skin cancer is most common among the elderly, but is now also more frequently found in younger people.
  • Surgery is often the treatment of choice and this is still the case in malignant melanoma and most cases of squamous cell carcinoma.
  • For basal cell carcinoma, Bowen's disease and actinic keratoses, however, alternative treatments should be considered.
  • Today, dermatologists can offer patients with skin cancer several new treatments besides surgery.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Melanoma / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Bowen's Disease / epidemiology. Bowen's Disease / therapy. Humans. Incidence. Prognosis. Sweden / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044750.001).
  • [ISSN] 0023-7205
  • [Journal-full-title] Läkartidningen
  • [ISO-abbreviation] Lakartidningen
  • [Language] swe
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Sweden
  • [Number-of-references] 20
  •  go-up   go-down


83. Nindl I, Gottschling M, Stockfleth E: Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers; 2007;23(4):247-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations.
  • Human papillomaviruses (HPV) infect cutaneous and mucosal epithelia and induce benign and malignant lesions.
  • Non-melanoma skin cancer (NMSC), encompassing basal cell carcinoma and squamous cell carcinoma (SCC), is the most frequent cancer in the Caucasian population, and the incidence has increased dramatically worldwide.
  • HPV types detected in skin tumours of these patients are referred to as EV/cutaneous HPV types belonging to the beta- and gamma-papillomaviruses (PV).
  • [MeSH-major] Papillomaviridae / pathogenicity. Papillomavirus Infections / complications. Skin Neoplasms / etiology
  • [MeSH-minor] Animals. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / virology. Disease Models, Animal. Epidermodysplasia Verruciformis / complications. Epidermodysplasia Verruciformis / virology. Humans. Immune Tolerance. Risk Factors. Transplantation Immunology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627060.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 155
  • [Other-IDs] NLM/ PMC3851066
  •  go-up   go-down


84. Bugatti L, Filosa G: Dermatoscopic features of cutaneous atypical fibroxanthoma: three cases. Clin Exp Dermatol; 2009 Dec;34(8):e898-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical fibroxanthoma (AFX) is an uncommon, low-grade, malignant, spindle-cell tumour of fibrohistiocytic histogenesis, which can mimic other malignant skin tumours, such as basal and squamous cell carcinoma (CC), melanoma, and Merkel cell carcinoma (MCC).
  • AFX may be added to the list of slightly pigmented, reddish, malignant cutaneous tumours, such as SCC, MCC, amelanotic/hypomelanotic melanoma and eccrine porocarcinoma, which display prominent and chaotic dermatoscopic neoangiogenetic features in more advanced stages of proliferation.
  • [MeSH-major] Dermoscopy / methods. Histiocytoma, Benign Fibrous / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055861.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Felder S, Rabinovitz H, Oliviero M, Kopf A: Dermoscopic differentiation of a superficial basal cell carcinoma and squamous cell carcinoma in situ. Dermatol Surg; 2006 Mar;32(3):423-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic differentiation of a superficial basal cell carcinoma and squamous cell carcinoma in situ.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Dermoscopy. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640692.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Euvrard S: [Skin cancers after organ transplants]. Presse Med; 2008 Oct;37(10):1475-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin cancers after organ transplants].
  • Squamous cell carcinoma and basal cell carcinoma are the most common cancers after transplants, affecting more than half of all patients in the long term.
  • In the 5 years after a first squamous cell carcinoma, 90 to 100% of transplant patients subsequently develop multiple skin carcinomas of various types and at least 20% develop noncutaneous cancers.
  • Management of these patients requires, beyond the usual dermatologic treatments, a revision of their immunosuppression regimen to reduce the tumor risk.
  • New immunosuppressants that inhibit the m-TOR protein (sirolimus and everolimus) appear to offer promising perspectives, and patients treated with these drugs from the time of their transplantation have fewer skin cancers than patients with the standard protocols.
  • Several prospective French multicenter studies are currently assessing the effect of replacing anticalcineurins by sirolimus or everolimus for secondary prevention of skin cancers in renal or cardiac transplant patients who have already developed skin cancer.
  • [MeSH-major] Organ Transplantation / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Herpesviridae Infections / complications. Herpesviridae Infections / diagnosis. Humans. Immunocompromised Host. Risk Factors. Xeroderma Pigmentosum / diagnosis. Xeroderma Pigmentosum / epidemiology. Xeroderma Pigmentosum / virology

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18775633.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


87. Zhao B, He YY: Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Rev Anticancer Ther; 2010 Nov;10(11):1797-809
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the prevention and treatment of skin cancer using photodynamic therapy.
  • Recently, PDT has been widely used in treating non-melanoma skin malignancies, the most common cancer in the USA, with superior cosmetic outcomes compared with conventional therapies.
  • After treatment with ALA or methyl 5-aminolevulinate, protoporphyrin IX preferentially accumulates in the lesion area of various skin diseases, which allows not only PDT treatment but also fluorescence diagnosis with ALA-induced porphyrins.
  • Susceptible lesions include various forms of non-melanoma skin cancer such as actinic keratosis, basal cell carcinoma and squamous cell carcinoma.
  • This article summarizes the main principles of PDT and its current clinical use in the management of non-melanoma skin cancers, as well as recent developments and possible future research directions.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):254-8 [16948827.001]
  • [Cites] Acta Derm Venereol. 2006;86(5):418-21 [16955186.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2006 Nov-Dec;22(6):498-9 [17117119.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):5-14 [17126737.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):89-94 [17126746.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):95-100 [17126747.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):264-5 [17310011.001]
  • [Cites] Expert Opin Drug Deliv. 2007 Mar;4(2):131-48 [17335411.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Apr;21(4):439-51 [17373968.001]
  • [Cites] Br J Dermatol. 2007 May;156(5):793-801 [17419691.001]
  • [Cites] Br J Dermatol. 2007 Jul;157(1):87-91 [17501954.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):462-9 [17657251.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1131-6 [17875873.001]
  • [Cites] Photomed Laser Surg. 2007 Oct;25(5):428-35 [17975957.001]
  • [Cites] Clin Transl Oncol. 2008 Mar;10(3):148-54 [18321817.001]
  • [Cites] Br J Dermatol. 2008 May;158(5):994-9 [18341663.001]
  • [Cites] Br J Pharmacol. 2008 May;154(1):1-3 [18362894.001]
  • [Cites] J Am Chem Soc. 2008 Aug 13;130(32):10643-7 [18642918.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):547-53 [18693158.001]
  • [Cites] Trends Biotechnol. 2008 Nov;26(11):612-21 [18804298.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Dec 14;60(15):1627-37 [18930086.001]
  • [Cites] Br J Dermatol. 2008 Dec;159(6):1245-66 [18945319.001]
  • [Cites] Exp Dermatol. 2009 Feb;18(2):116-21 [18643849.001]
  • [Cites] Chem Commun (Camb). 2009 Mar 28;(12):1475-7 [19277361.001]
  • [Cites] Photodiagnosis Photodyn Ther. 2008 Jun;5(2):127-33 [19356643.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 May;23(5):505-16 [19175703.001]
  • [Cites] Br J Dermatol. 2009 Jun;160(6):1308-14 [19416257.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Jul;29(7):992-1000 [19057023.001]
  • [Cites] Nat Med. 2009 Jul;15(7):713 [19584845.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Dec 1;241(2):163-72 [19695274.001]
  • [Cites] J Pathol. 2009 Dec;219(4):400-9 [19771562.001]
  • [Cites] Immunol Res. 2010 Mar;46(1-3):216-26 [19763892.001]
  • [Cites] Arch Dermatol. 2010 Mar;146(3):283-7 [20231499.001]
  • [Cites] Eur J Dermatol. 2000 Oct-Nov;10(7):568-75; discussion 576 [11056436.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2314-7 [11186878.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2000 Jul;14(4):298-300 [11204521.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Mar;15(3):311-21 [11207506.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Br J Dermatol. 2001 Jun;144(6):1207-14 [11422043.001]
  • [Cites] Br J Dermatol. 2001 Sep;145(3):467-71 [11531838.001]
  • [Cites] J Photochem Photobiol B. 2001 Sep 15;62(3):140-5 [11566277.001]
  • [Cites] Photochem Photobiol. 2001 Nov;74(5):656-69 [11723793.001]
  • [Cites] J Chemother. 2001 Oct;13(5):494-502 [11760213.001]
  • [Cites] J Photochem Photobiol B. 2002 Mar;66(2):89-106 [11897509.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2005 Jun;21(3):142-9 [15888131.001]
  • [Cites] J Photochem Photobiol B. 2005 Jun 1;79(3):231-41 [15896650.001]
  • [Cites] Australas J Dermatol. 2005 Aug;46(3):196-8 [16008656.001]
  • [Cites] Br J Dermatol. 2005 Sep;153(3):672-4 [16120168.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Dec;56(6):569-77 [16001166.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):791-800 [16221049.001]
  • [Cites] J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S273-6 [16227107.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):146-9 [16403108.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):542-4 [16482195.001]
  • [Cites] J Am Acad Dermatol. 2006 Mar;54(3):524-6 [16488310.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] Optom Vis Sci. 2002 Apr;79(4):218-24 [11999147.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3956-61 [12124326.001]
  • [Cites] Lasers Med Sci. 2002;17(3):173-86 [12181632.001]
  • [Cites] Clin Exp Dermatol. 2002 Sep;27(6):516-8 [12372098.001]
  • [Cites] Methods Mol Med. 2003;75:507-26 [12407761.001]
  • [Cites] J Photochem Photobiol B. 2003 Feb;69(2):121-7 [12633984.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] J Am Chem Soc. 2003 Jul 2;125(26):7860-5 [12823004.001]
  • [Cites] Mol Immunol. 2003 Jul;39(17-18):1133-6 [12835091.001]
  • [Cites] J Dermatolog Treat. 2003;14 Suppl 3:23-6 [14522638.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3591-600 [14666654.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Dermatol Surg. 2004 Jan;30(1):63-6 [14692930.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):115-21 [14724445.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):116-20 [14732670.001]
  • [Cites] J Am Acad Dermatol. 2004 Mar;50(3):363-7 [14988676.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):337-40 [14996106.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):295-300 [15069697.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1061-9 [15214890.001]
  • [Cites] Australas J Dermatol. 2004 Aug;45(3):172-4 [15250896.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Aug;5(4):397-408 [15320770.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):472-80 [15327557.001]
  • [Cites] Onkologie. 2004 Aug;27(4):407-11 [15347900.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 May;130(5):279-84 [14997383.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Aust N Z J Surg. 1991 May;61(5):340-8 [2025186.001]
  • [Cites] Photochem Photobiol. 1991 Nov;54(5):659 [1798741.001]
  • [Cites] Photochem Photobiol. 1992 Jun;55(6):931-48 [1409894.001]
  • [Cites] Arch Dermatol Res. 1995;287(7):665-74 [8534131.001]
  • [Cites] J Urol. 1996 Jan;155(1):105-9; discussion 109-10 [7490803.001]
  • [Cites] Photochem Photobiol. 1996 Jun;63(6):892-7 [8992510.001]
  • [Cites] Dermatology. 1996;192(3):246-51 [8726640.001]
  • [Cites] J Photochem Photobiol B. 1996 Nov;36(2):169-74 [9002254.001]
  • [Cites] J Photochem Photobiol B. 1996 Nov;36(2):199-204 [9002261.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2282-308 [9191516.001]
  • [Cites] Arch Dermatol. 1997 Jun;133(6):727-32 [9197826.001]
  • [Cites] Photochem Photobiol. 1997 Oct;66(4):493-6 [9337620.001]
  • [Cites] Aesthetic Plast Surg. 1997 Nov-Dec;21(6):437-9 [9354609.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):207-14 [9487213.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):746-51 [9579539.001]
  • [Cites] Australas J Dermatol. 1998 May;39(2):63-8; quiz 69-70 [9611372.001]
  • [Cites] J Clin Laser Med Surg. 1996 Oct;14(5):219-21 [9612186.001]
  • [Cites] Acta Derm Venereol. 1999 Jan;79(1):54-61 [10086861.001]
  • [Cites] Br J Dermatol. 1999 Mar;140(3):514-7 [10233277.001]
  • [Cites] J Invest Dermatol. 1959 Feb;32(2, Part 2):229-31 [13641790.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jan 7;44(3):419-23 [15624158.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):13-8 [15672050.001]
  • [Cites] Breast. 2005 Feb;14(1):65-7 [15695084.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):338-9 [10730770.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):825-6 [10792247.001]
  • [Cites] Cancer. 2000 May 15;88(10):2275-82 [10820349.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):396-401 [10951274.001]
  • [Cites] J Urol. 2006 Apr;175(4):1201-7 [16515960.001]
  • [Cites] Br J Dermatol. 2006 Apr;154(4):747-50 [16536822.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2006;25(1-2):441-51 [16566734.001]
  • [Cites] Acta Derm Venereol. 2006;86(1):25-8 [16585985.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):551-6 [16700893.001]
  • [Cites] Int J Dermatol. 2006 May;45(5):489-98 [16700779.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • (PMID = 21080805.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES016936-01A2; United States / NCI NIH HHS / CA / P30 CA014599; United States / NIEHS NIH HHS / ES / R01 ES016936; United States / Intramural NIH HHS / / ZIA ES050117-21; United States / NIEHS NIH HHS / ES / ES016936-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS263919; NLM/ PMC3030451
  •  go-up   go-down


88. Chan S, Dhadda AS, Swindell R: Single fraction radiotherapy for small superficial carcinoma of the skin. Clin Oncol (R Coll Radiol); 2007 May;19(4):256-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single fraction radiotherapy for small superficial carcinoma of the skin.
  • AIMS: To define the optimal dose and maximum tumour size of basal and squamous cell carcinoma of skin that can be treated by single fraction radiotherapy.
  • MATERIALS AND METHODS: A review was undertaken of 1005 lesions of basal/squamous cell carcinoma of the skin involving 806 patients treated at a single centre with 10 years of follow-up.
  • RESULTS: The overall disease-free and necrosis-free rates at 5 years were 90% and 84%, respectively.
  • The crude 10-year recurrence rate was 4% (95% CI 3.4-5.4%), with late skin necrosis at 6% (95% CI 4.8-7.2%).
  • There was no difference in tumour recurrence rates between 20 and 22.5 Gy (P=0.3), but there was a significantly higher skin necrosis rate at the treated site in the patients who had received 22.5 Gy (P=0.003).
  • Most skin necrosis healed spontaneously, with only 16% requiring surgical intervention.
  • CONCLUSIONS: Single fraction radiotherapy is an acceptable treatment for small superficial BCC and SCC of the head and neck region in patients who have difficulty attending multiple hospital visits as long as the field size required for treatment is no larger than 3 cm in diameter.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / mortality. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Disease-Free Survival. England / epidemiology. Female. Humans. Male. Medical Records. Middle Aged. Necrosis / pathology. Radiation Dosage. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379488.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Hong H, Sun J, Cai W: Anatomical and molecular imaging of skin cancer. Clin Cosmet Investig Dermatol; 2008;1:1-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomical and molecular imaging of skin cancer.
  • Skin cancer is the most common form of cancer types.
  • It is generally divided into two categories: melanoma (∼ 5%) and nonmelanoma (∼ 95%), which can be further categorized into basal cell carcinoma, squamous cell carcinoma, and some rare skin cancer types.
  • Biopsy is still the gold standard for skin cancer evaluation in the clinic.
  • Various anatomical imaging techniques have been used to evaluate different types of skin cancer lesions, including laser scanning confocal microscopy, optical coherence tomography, high-frequency ultrasound, terahertz pulsed imaging, magnetic resonance imaging, and some other recently developed techniques such as photoacoustic microscopy.
  • However, anatomical imaging alone may not be sufficient in guiding skin cancer diagnosis and therapy.
  • Over the last decade, various molecular imaging techniques (in particular single photon emission computed tomography and positron emission tomography) have been investigated for skin cancer imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Arztl Fortbild Qualitatssich. 1997 Jul;91(4):347-53 [9340205.001]
  • [Cites] Radiographics. 1997 Nov-Dec;17(6):1559-65 [9397463.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1770-6 [9586890.001]
  • [Cites] NMR Biomed. 2008 Mar;21(3):296-300 [18246539.001]
  • [Cites] J Biomed Opt. 2008 Jan-Feb;13(1):014003 [18315361.001]
  • [Cites] Adv Exp Med Biol. 2008;624:215-26 [18348459.001]
  • [Cites] Adv Exp Med Biol. 2008;624:227-40 [18348460.001]
  • [Cites] Adv Exp Med Biol. 2008;624:296-318 [18348465.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S [18523069.001]
  • [Cites] Opt Express. 2002 Jul 29;10(15):707-13 [19451924.001]
  • [Cites] Biotechniques. 2005 Dec;39(6 Suppl):S6-13 [20158503.001]
  • [Cites] J Nucl Med. 1990 Nov;31(11):1831-5 [2230996.001]
  • [Cites] Ann Surg. 1986 Sep;204(3):223-35 [3753057.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:697-715 [8970741.001]
  • [Cites] Dermatol Surg. 1997 Jan;23(1):43-5 [9107293.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12814-8 [9788997.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1347-51 [9811323.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):457-61 [9930803.001]
  • [Cites] Nucl Med Biol. 1999 Aug;26(6):687-93 [10587108.001]
  • [Cites] Crit Rev Oncog. 2000;11(2):147-63 [11005510.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5649-58 [11059756.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4474-82 [11389078.001]
  • [Cites] Nucl Med Biol. 2001 Jul;28(5):493-8 [11516693.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1847-55 [11752084.001]
  • [Cites] Nucl Med Biol. 2006 Aug;33(6):723-33 [16934691.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):913-21 [17146742.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):81-4 [17199571.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):64-72 [17204700.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):73-80 [17204701.001]
  • [Cites] Cancer Imaging. 2006;6:204-8 [17208677.001]
  • [Cites] Bull Cancer. 2007 Jan;94(1):93-8 [17237009.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):304-10 [17268029.001]
  • [Cites] J Nucl Med. 2007 Mar;48(3):429-36 [17332621.001]
  • [Cites] Bioconjug Chem. 2007 May-Jun;18(3):765-72 [17348700.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):421-5; discussion 425-6 [17430375.001]
  • [Cites] Front Biosci. 2007;12:4514-24 [17485393.001]
  • [Cites] Rofo. 2007 Jun;179(6):618-26 [17492539.001]
  • [Cites] Nucl Med Biol. 2007 May;34(4):363-70 [17499725.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):987-94 [17504880.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Apr;16(2):403-30 [17560520.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):629-37 [17610989.001]
  • [Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]
  • [Cites] Arch Dermatol. 2007 Jul;143(7):883-6 [17638732.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Jun;22(3):333-41 [17651039.001]
  • [Cites] Cutis. 2007 Mar;79(3):241-8 [17674590.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1158-74 [17903149.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1220-7; discussion 1226-7 [17903155.001]
  • [Cites] J Radiol. 1998 Apr;79(4):313-7 [9757255.001]
  • [Cites] Eur J Nucl Med. 1998 Oct;25(10):1383-9 [9818277.001]
  • [Cites] Bioconjug Chem. 2006 May-Jun;17(3):662-9 [16704203.001]
  • [Cites] J Dermatol Sci. 2006 Aug;43(2):135-41 [16806842.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):408-12 [16908344.001]
  • [Cites] J Nucl Med. 1999 Apr;40(4):591-603 [10210218.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2917-23 [10383155.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(4):343-8 [10447583.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):42-8 [10863222.001]
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):9-25 [10933065.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2674-8 [11352959.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Science. 2001 Oct 12;294(5541):339-45 [11546839.001]
  • [Cites] Hybrid Hybridomics. 2001;20(5-6):351-60 [11839253.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Pigment Cell Res. 2003 Jun;16(3):266-72 [12753400.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3172-9 [12789293.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1279-83 [13679435.001]
  • [Cites] Nat Biotechnol. 2003 Nov;21(11):1361-7 [14595364.001]
  • [Cites] Bioconjug Chem. 2003 Nov-Dec;14(6):1177-84 [14624632.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):61-9 [14733584.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1411-8 [14973076.001]
  • [Cites] Magn Reson Imaging. 2004 Jul;22(6):843-50 [15234453.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):469-74 [15529179.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):121-9 [15632042.001]
  • [Cites] Skin Res Technol. 2007 Nov;13(4):463-71 [17908200.001]
  • [Cites] Dermatology. 2007;215(4):365-72 [17912001.001]
  • [Cites] Panminerva Med. 2007 Sep;49(3):119-38 [17912148.001]
  • [Cites] Nucl Med Biol. 2007 Nov;34(8):945-53 [17998097.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Dec;7(12):1707-16 [18062745.001]
  • [Cites] Int J Pharm. 2008 Apr 2;353(1-2):233-42 [18191509.001]
  • [Cites] Bioconjug Chem. 2008 Feb;19(2):539-47 [18197608.001]
  • [Cites] Skin Res Technol. 2008 Feb;14(1):18-25 [18211598.001]
  • [Cites] Skin Res Technol. 2008 Feb;14(1):89-92 [18211606.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):329-33 [18215250.001]
  • [Cites] Dermatol Surg. 2008 May;34(5):610-9 [18261097.001]
  • [Cites] Anal Sci. 2008 Feb;24(2):185-92 [18270407.001]
  • [Cites] Curr Opin Oncol. 2008 Mar;20(2):196-200 [18300770.001]
  • [Cites] Int J Cosmet Sci. 2008 Feb;30(1):1-17 [18377626.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 May;22(5):606-15 [18410618.001]
  • [Cites] J Nucl Med. 2008 May;49(5):823-9 [18413404.001]
  • [Cites] Clin Nucl Med. 2008 May;33(5):353-5 [18431156.001]
  • [Cites] J Nucl Med. 2008 Jun;49(6):879-86 [18483090.001]
  • [Cites] Semin Cutan Med Surg. 2008 Mar;27(1):37-43 [18486023.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jul;191(1):285-9 [18562760.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):904s-908s [2297740.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):941s-948s [2297746.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3445-52 [2334941.001]
  • [Cites] Neoplasma. 1989;36(5):505-11 [2812147.001]
  • [Cites] J Nucl Med. 1988 Mar;29(3):329-37 [3346743.001]
  • [Cites] Biomed Pharmacother. 1986;40(10):392-8 [3580508.001]
  • [Cites] Cancer Immunol Immunother. 1987;24(3):221-4 [3594484.001]
  • [Cites] NCI Monogr. 1987;(3):3-9 [3821916.001]
  • [Cites] Radiology. 1985 May;155(2):487-92 [3983400.001]
  • [Cites] Cancer Res. 1985 Jul;45(7):3378-87 [4005860.001]
  • [Cites] Br J Urol. 1994 Oct;74(4):521-2 [7820438.001]
  • [Cites] Arch Dermatol. 1995 Mar;131(3):279-85 [7887656.001]
  • [Cites] Int J Cancer. 1994 Sep 1;58(5):749-55 [8077062.001]
  • [Cites] Melanoma Res. 1993 Dec;3(6):395-401 [8161879.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):525-32 [8504043.001]
  • [Cites] Clin Nucl Med. 1997 Jan;22(1):25-9 [8993869.001]
  • [Cites] Nucl Med Biol. 1997 Feb;24(2):171-8 [9089709.001]
  • [Cites] Bioconjug Chem. 1997 May-Jun;8(3):347-53 [9177840.001]
  • [Cites] Magn Reson Med. 2005 Mar;53(3):621-7 [15723405.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e70 [15783258.001]
  • [Cites] Mol Imaging. 2004 Oct;3(4):343-51 [15802051.001]
  • [Cites] J Med Chem. 2005 Apr 21;48(8):2985-92 [15828837.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1250-5 [16258537.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S127-47 [16446711.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):638-43 [16546585.001]
  • [Cites] J Nucl Med. 2006 May;47(5):763-9 [16644745.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):957-67 [16741305.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3942-9 [16818691.001]
  • [Cites] Nat Biotechnol. 2006 Jul;24(7):848-51 [16823374.001]
  • [Cites] J Nucl Med. 2006 Sep;47(9):1434-9 [16954550.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2624-33 [17121909.001]
  • [Cites] J Dermatol Sci. 2007 Mar;45(3):167-73 [17215110.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2005;1:190-2 [17282143.001]
  • [Cites] Melanoma Res. 2007 Apr;17(2):117-27 [17496787.001]
  • [Cites] Tech Vasc Interv Radiol. 2006 Sep;9(3):125-32 [17561215.001]
  • [Cites] Arch Dermatol. 2007 Jun;143(6):727-34 [17576938.001]
  • [Cites] J Dtsch Dermatol Ges. 2007 Aug;5(8):689-707 [17659044.001]
  • [Cites] Int J Dermatol. 2007 Sep;46(9):895-904 [17822489.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):186-208 [17846765.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17489-93 [17954911.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1633-42 [18020929.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:56-8 [18067634.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):101-9 [18202013.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1196-201 [11877745.001]
  • [Cites] Phys Med Biol. 2002 Apr 7;47(7):R67-84 [11996068.001]
  • [Cites] J Med Chem. 2002 Jul 4;45(14):3048-56 [12086490.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):646-53 [12167578.001]
  • [Cites] Phys Med Biol. 2002 Nov 7;47(21):3847-52 [12452576.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1699-706 [12468522.001]
  • [Cites] J Invest Dermatol. 2003 Jan;120(1):72-8 [12535200.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1210-8 [12902409.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2545-8 [1314697.001]
  • [Cites] Science. 1992 Aug 28;257(5074):1248-51 [1325670.001]
  • [Cites] Br J Dermatol. 2003 Nov;149(5):1035-40 [14632811.001]
  • [Cites] Optometry. 2003 Dec;74(12):760-4 [14677727.001]
  • [Cites] Klin Monbl Augenheilkd. 2003 Dec;220(12):822-9 [14704937.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):116-23 [14734683.001]
  • [Cites] Nuklearmedizin. 2004 Feb;43(1):26-32 [14978538.001]
  • [Cites] Br J Dermatol. 2004 Apr;150(4):677-86 [15099363.001]
  • [Cites] Ann Surg Oncol. 2004 Aug;11(8):731-8 [15249335.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1323-7 [15299056.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):458-63 [15304083.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):424-32 [15327550.001]
  • [Cites] Cancer J. 2004 Jul-Aug;10(4):262-70 [15383207.001]
  • [Cites] Vestn Rentgenol Radiol. 2004 Mar-Apr;(2):44-54 [15458273.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2004 Dec;20(6):283-8 [15533235.001]
  • [Cites] Phys Med Biol. 2004 Nov 7;49(21):N363-9 [15584535.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):217-24 [15724019.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):269-70 [15724029.001]
  • [Cites] Curr Opin Oncol. 2005 Mar;17(2):154-9 [15725921.001]
  • [Cites] J Nucl Med. 2005 May;46(5):887-95 [15872364.001]
  • [Cites] Curr Opin Oncol. 1992 Apr;4(2):380-5 [1591311.001]
  • [Cites] Nucl Med Biol. 2005 Jul;32(5):485-93 [15982579.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):195-222 [15986132.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5616-21 [16061880.001]
  • [Cites] J Dermatol Sci. 2005 Nov;40(2):85-94 [16139481.001]
  • [Cites] Radiology. 1992 Aug;184(2):427-34 [1620841.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):054010 [16292970.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):979-85 [16310058.001]
  • [Cites] Arch Dermatol. 2006 Mar;142(3):393; author reply 393 [16549724.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):193-200 [16615102.001]
  • (PMID = 21437135.001).
  • [ISSN] 1178-7015
  • [Journal-full-title] Clinical, cosmetic and investigational dermatology
  • [ISO-abbreviation] Clin Cosmet Investig Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3048596
  • [Keywords] NOTNLM ; anatomical imaging / antibody / melanoma / molecular imaging / positron emission tomography / skin cancer
  •  go-up   go-down


90. Quatresooz P, Piérard GE, Paquet P, Blaise G, Piérard-Franchimont C: [Cutaneous cancers after organ transplantation]. Rev Med Liege; 2007 Nov;62(11):663-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cancers cutanés après transplantation d'organe, un revers de médaille.
  • Cutaneous carcinomas are the most frequent malignancies developing after organ transplantation.
  • The usual squamous to basal cell carcinoma ratio is increased and reversed compared to the general population.
  • Carcinomas primarily result from the combination of cumulative sun exposure, fair skin phototype and effects of immunosuppressive drugs.
  • The severity of these carcinomas is due to their multiplicity and to the occurrence of more aggressive lesions.
  • The treatment of the neoplastic lesions is based on their early and complete excision with histological control of the nature of the neoplasm, the safety surgical margins, and the determination of prognostic factors.
  • [MeSH-major] Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects. Organ Transplantation. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217642.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 43
  •  go-up   go-down


91. Baron ED, Malbasa CL, Santo-Domingo D, Fu P, Miller JD, Hanneman KK, Hsia AH, Oleinick NL, Colussi VC, Cooper KD: Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. Lasers Surg Med; 2010 Dec;42(10):728-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial.
  • BACKGROUND: Photodynamic therapy (PDT) is a non-invasive treatment for non-melanoma skin cancer.
  • STUDY DESIGN/MATERIALS AND METHODS: Forty three adults with a diagnosis of neoplasms including actinic keratoses, Bowen's disease, squamous cell carcinoma, basal cell carcinoma, or mycosis fungoides were treated with a single administration of Pc 4-PDT and followed for 14 days.
  • It has promising biologic effects, particularly in mycosis fungoides where 14 of 35 subjects demonstrated a clinical response, which correlates with Pc 4-PDT-induced apoptosis, as measured by increased active caspase-3 in the treated skin lesions.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • [Cites] Arch Oral Biol. 1998 Feb;43(2):143-9 [9602293.001]
  • [Cites] Photochem Photobiol. 1997 Mar;65(3):581-6 [9077144.001]
  • [Cites] J Am Acad Dermatol. 1999 Mar;40(3):418-25 [10071312.001]
  • [Cites] Am J Public Health. 1999 Aug;89(8):1240-4 [10432915.001]
  • [Cites] Arch Dermatol. 2005 Mar;141(3):305-11 [15781671.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):254-8 [16948827.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):86-107 [17693025.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):407-14 [18221452.001]
  • [Cites] Photochem Photobiol Sci. 2009 Aug;8(8):1111-6 [19639112.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Dec 1;241(2):163-72 [19695274.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):765-9; discussion 769-70 [10940064.001]
  • [Cites] J Invest Dermatol. 2000 Dec;115(6):1041-6 [11121139.001]
  • [Cites] Exp Cell Res. 2001 Feb 1;263(1):145-55 [11161713.001]
  • [Cites] Acta Derm Venereol. 2001 Jun-Jul;81(3):184-8 [11558874.001]
  • [Cites] Cancer Lett. 2002 May 8;179(1):43-9 [11880181.001]
  • [Cites] Arch Dermatol. 2002 Mar;138(3):325-32 [11902983.001]
  • [Cites] Clin Exp Dermatol. 2002 Sep;27(6):493-7 [12372093.001]
  • [Cites] Eur J Med Res. 2002 Nov 25;7(11):477-9 [12568975.001]
  • [Cites] Photochem Photobiol Sci. 2002 Jan;1(1):1-21 [12659143.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Am Acad Dermatol. 1989 Mar;20(3):416-28 [2537348.001]
  • [Cites] J Am Acad Dermatol. 1990 May;22(5 Pt 1):802-10 [2347966.001]
  • [Cites] Photochem Photobiol. 1999 Feb;69(2):236-41 [10048316.001]
  • (PMID = 21246576.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024989; United States / NIAMS NIH HHS / AR / P30 AR039750; United States / NIAMS NIH HHS / AR / AR39750; United States / NIAMS NIH HHS / AR / P30 AR039750-19; United States / NCRR NIH HHS / RR / M01 RR00080; United States / NIAMS NIH HHS / AR / P30 AR039750-18; United States / NCI NIH HHS / CA / P01 CA48735; United States / NIAMS NIH HHS / AR / AR039750-20; United States / NIAMS NIH HHS / AR / P30 AR039750-20; United States / NIAMS NIH HHS / AR / AR039750-18; United States / NCI NIH HHS / CA / P01 CA048735; United States / NCRR NIH HHS / RR / M01 RR000080
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Organosilicon Compounds; 0 / Photosensitizing Agents; 135719-28-7 / silicon phthalocyanine
  • [Other-IDs] NLM/ NIHMS314763; NLM/ PMC3149858
  •  go-up   go-down


92. Lim P, Paver R, Peñas PF: Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007). J Am Acad Dermatol; 2010 Nov;63(5):832-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007).
  • OBJECTIVE: We sought to evaluate changes over time in the type of patients and skin cancers that are treated using MMS, and the repairs used to close the defects.
  • METHODS: We conducted a retrospective study on patients treated with MMS at the Skin and Cancer Foundation Australia, Westmead, in 1997 against those treated in 2007.
  • Patient demographics (age, sex), pathology of tumor, anatomic site of the tumor, preoperative tumor size, postoperative defect size, and repair method were analyzed.
  • The 2007 cohort was a little older (62 vs 64 years), but there were no differences in sex, anatomic site, rate of basal/squamous cell carcinoma, squamous cell carcinoma histologic subtypes, or preoperative tumor size.
  • However, there were fewer superficial basal cell carcinomas, and the postoperative defect size was smaller in 2007 (P < .0001).
  • CONCLUSION: Although tumor size and the percentage of tumors in each anatomic site did not change over 10 years, the size of the defect created after MMS has become smaller.
  • This reduction in defect size may explain why more defects are now repaired by side-to-side closure and flap repairs whereas fewer defects are repaired by skin grafting.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Mohs Surgery / statistics & numerical data. Mohs Surgery / utilization. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Australia / epidemiology. Cohort Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Skin Transplantation / statistics & numerical data. Skin Transplantation / utilization. Surgical Flaps / statistics & numerical data. Surgical Flaps / utilization

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20950738.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Pons M, Quintanilla M: Molecular biology of malignant melanoma and other cutaneous tumors. Clin Transl Oncol; 2006 Jul;8(7):466-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of malignant melanoma and other cutaneous tumors.
  • Skin cancer is the most common cancer worldwide.
  • In this review, we summarize the most important genetic changes contributing to the development of malignant melanoma, basal cell carcinoma and squamous cell carcinoma, the main tumor entities arising in the skin.
  • While our understanding of the oncogenes and tumor suppressor genes involved in the development and progression of skin tumors is still fragmentary, recent advances have shown alterations affecting conserved signalling pathways that control cellular proliferation and viability.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic. Genes, Tumor Suppressor. Melanoma / pathology. Oncogenes. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 May;2(5):361-72 [12044012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13312-7 [11606789.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 21;92(12):1006-10 [10861313.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2262-9 [16306523.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):65-79 [15748639.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2004 Nov 15;131C(1):82-92 [15468170.001]
  • [Cites] J Cutan Pathol. 2005 Mar;32(3):191-205 [15701081.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Nat Genet. 1996 Sep;14 (1):78-81 [8782823.001]
  • [Cites] Lancet. 2002 Jan 5;359(9300):7-8 [11809177.001]
  • [Cites] Int J Dermatol. 2003 Sep;42(9):669-76 [12956675.001]
  • [Cites] Pediatrics. 2004 Apr;113(4 Suppl):1114-9 [15060207.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):559-70 [12894244.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(2):261-84 [10728988.001]
  • [Cites] Cancer Lett. 2005 Jul 28;225(2):181-92 [15978322.001]
  • [Cites] Semin Cancer Biol. 2004 Feb;14(1):63-9 [14757536.001]
  • [Cites] Cancer Cell. 2005 Dec;8(6):439-41 [16338657.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1657-67 [15905207.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):153-86 [16297704.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1284-92 [15140233.001]
  • [Cites] Br J Dermatol. 2005 Jun;152(6):1108-24 [15948971.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):43-56 [15748637.001]
  • [Cites] Nature. 1994 Dec 22-29;372(6508):773-6 [7997263.001]
  • (PMID = 16870533.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 23
  •  go-up   go-down


94. Okuyama R, Tagami H, Aiba S: Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J Dermatol Sci; 2008 Mar;49(3):187-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases.
  • Skin undergoes self-renewal throughout life.
  • Terminally differentiated keratinocytes, namely the corneocytes, are continually shed from the surface of the skin, whereas immature cells produce progeny that proceed through the differentiation process.
  • Notch signaling controls a number of cellular processes including cell fate decision, proliferation, differentiation and survival/apoptosis.
  • Hence, Notch and its ligands are expressed in multiple tissues including the skin, where they are abundantly expressed in the epidermis.
  • Notch activation results in the promotion of growth arrest and the onset of differentiation, therefore suggesting that specific Notch activation may regulate skin homeostasis by balancing these processes, i.e.
  • Notch signaling functions as a molecular switch that controls the transition of cells between skin layers during the epidermal differentiation process.
  • Recent advances in the study of Notch signaling have confirmed that there is cross-talk between the Notch signaling pathway and a variety of other signaling molecules including Sonic hedgehog (Shh), beta-catenin and the p53 family member, p63.
  • In addition, Notch counteracts the action of p63 to maintain immature cell characteristics.
  • However, aberrant Notch signaling results in the development of psoriasis and skin cancers such as squamous cell carcinoma, basal cell carcinoma and malignant melanoma.
  • Future efforts to further define how Notch controls cell proliferation and differentiation may lead to the application of Notch in new therapies for various skin diseases.
  • [MeSH-major] Receptors, Notch / physiology. Signal Transduction / physiology. Skin / cytology. Skin Diseases / etiology
  • [MeSH-minor] Animals. Cell Differentiation. Cell Proliferation. Homeostasis. Humans. Langerhans Cells / physiology. Melanocytes / physiology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624739.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Notch
  • [Number-of-references] 67
  •  go-up   go-down


95. Tran KT, Lamb P, Deng JS: Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. J Dermatol Sci; 2005 Oct;40(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrikines and matricryptins: Implications for cutaneous cancers and skin repair.
  • Dermatologists are faced daily with the need to optimize skin repair and excise cutaneous cancers.
  • The extracellular matrix plays a pivotal role in cellular migration, proliferation, and gene regulation during wound healing and progression of melanoma, basal cell carcinoma, and squamous cell carcinoma.
  • Within the last few years, a new class of ligand, the matrikine or matricryptin, has been characterized as subdomains of various ECM proteins capable of signaling to the cell through receptors, such as growth factor receptors.
  • The EGF-like repeats of tenascin-C and laminin-5 signal to EGFR preferentially to upregulate migration during skin repair and tumor progression.
  • Within the next few years, the nature and function of this emerging class of matrikine ligands will have an impact on dermatology, as these proteins are altered in wound repair and skin diseases.
  • [MeSH-major] Extracellular Matrix Proteins / physiology. Skin Neoplasms / etiology
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Adhesion Molecules / physiology. Collagen / physiology. Humans. Ligands. Molecular Sequence Data. Signal Transduction. Tenascin / physiology. Tissue Engineering. Wound Healing

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15993569.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Extracellular Matrix Proteins; 0 / Ligands; 0 / Tenascin; 0 / kalinin; 9007-34-5 / Collagen
  • [Number-of-references] 50
  •  go-up   go-down


96. Miller KL, Karagas MR, Kraft P, Hunter DJ, Catalano PJ, Byler SH, Nelson HH: XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis; 2006 Aug;27(8):1670-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XPA, haplotypes, and risk of basal and squamous cell carcinoma.
  • Nucleotide excision repair (NER) is instrumental in removing DNA lesions caused by ultraviolet (UV) radiation, the dominant risk factor for keratinocyte carcinoma, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • We evaluated whether BCC or SCC risk was influenced by the A23G single nucleotide polymorphism (SNP) in Xeroderma pigmentosum group A (XPA), which codes for an essential protein in NER.
  • We also investigated whether haplotypes of XPA, determined by seven haplotype-tagging SNPs, better define susceptibility to keratinocyte carcinoma.
  • Incident cases of BCC and SCC from New Hampshire were identified through dermatologists and pathology laboratories.
  • Cases of BCC (886) and of SCC (682) were compared with controls (796).
  • Using GG as the reference, the A allele was less frequent among cases of BCC (OR(AG) = 0.82, 95% CI (0.66, 1.01); OR(AA)= 0.74, 95% CI (0.53, 1.03); trend test P = 0.03) and SCC (OR(AG) = 0.85, 95% CI (0.67, 1.07); OR(AA) = 0.74, 95% CI (0.52, 1.05); trend test P = 0.05) than controls.
  • Risk from > or =3 severe sunburns was elevated for those with the GG genotype only, and this interaction was nearly significant for BCC (P = 0.07).
  • Using a haplotype analysis identifying seven common XPA haplotypes indicated that the A23G polymorphism alone captured the differences in susceptibility to keratinocyte carcinoma.
  • The common G allele of the A23G polymorphism was associated with an increased risk of BCC and SCC and this polymorphism appeared to be the determining polymorphism in XPA that alters cancer susceptibility.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Haplotypes / genetics. Skin Neoplasms / genetics. Xeroderma Pigmentosum Group A Protein / genetics